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ABSTRACT
ANALYSIS OF MECP2 GENE MUTATIONS IN TURKISH RETT
SYNDROME PATIENTS
Ayça Sayı
M.S. in Molecular Biology and Genetics
Supervisor: Assoc. Prof. Dr. Tayfun Özçelik
August 2001,  111 pages
Rett Syndrome (RTT) is a progressive X-linked dominant childhood neurodevelopmental
disorder, affecting 1/10,000-15,000 girls.  The disease-causing gene was identified as
MECP2 on chromosome Xq28, and mutations have been found in approximately 80% of
patients diagnosed with RTT.  We screened for eight recurrent MECP2 mutations
(R106W, P152R, T158M, R306C, R168X), one rare mutation (F155S) and one
polymorphism (E397K) in 63 RTT patients divided into four groups as classic-RTT
(n=43), variant-RTT (n=14), male-RTT (n=4), and familial-RTT (n=2).  We identified
the recurrent mutations in 18 cases.  These are three R106W, two P152R, five T158M,
five R306C, and three R270X mutations.  R168X and F155S were not detected in our
patients. Only one patient had the E397K polymorphism who also had the R306C
mutation.  All these mutations were confirmed via sequencing analysis.  In exon 4 of
MECP2, several deletion types of mutations are known. By PCR analysis, two patients
were found to have an approximately 44 bp deletion in exon 4.  Also, a novel mutation –
T197M– was identified in one of the patients.  We identified a boy affected by RTT who
is mosaic for the R270X mutation, and had a normal male karyotype. This result show
that a recurrent MECP2 mutation could lead to a similar phenotype in females and males,
if the male is a mosaic for the mutation in his somatic cells.  MECP2 mutation frequency
for the four groups is as follows: 37.2% for the classic-RTT, 28.57% for the variant-
RTT, and 25% for the male-RTT groups.  No mutation was found in the familial group.
We could not find a consistent correlation between the clinical symptoms and the type of
mutations or the X chromosome inactivation patterns of the patients.
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ÖZET
TÜRK RETT SENDROMU HASTALARINDA MECP2 GENİNDEKİ
MUTASYONLARIN ANALİZİ
Ayça Sayı
Moleküler Biyoloji ve Genetik Yüksek Lisans
Tez Yöneticisi: Doç. Dr. Tayfun Özçelik
Ağustos 2001,  111 sayfa
Rett Sendromu (RTT) X'e bağlı dominant kalıtım gösteren, ilerleyici özellikte, bir
çocukluk dönemi nöral gelişim hastalığıdır.  Büyük bir çoğunlukla kızları etkiler ve
1/10,000-15,000 sıklıkla görülür.  Hastalığa neden olan genin Xq28'de bulunan MECP2
olduğu tanımlanmıştır. RTT tanısı konan hastaların yaklaşık %80'inde bu genin
mutasyonu bulunmuştur.  Biz 63 RTT hastasını klasik-RTT (n=43), RTT-varyant (n=14),
erkek-RTT (n=4) ve ailesel-RTT (n=2) olmak üzere dört gruba ayırdık ve bu hastalarda
sekiz adet sık gözüken mutasyonu (R106W, P152R, T158M, R306C, R168X), bir adet
nadir gözüken mutasyonu (F155S), ve bir adet polimorfizmi (E397K) taradık.  Üç
hastada R106W, iki hastada P152R, beş hastada T158M, beş hastada R306C ve üç
hastada R270X mutasyonu olmak üzere toplam onsekiz sık gözüken mutasyonu saptadık.
Bizim hastalarımızda R168X ve F155S mutasyonları bulunamamıştır. R306C mutasyonu
olan bir hastada aynı zamanda E397K polimorfizmi saptanmıştır.  Tüm bu mutasyonların
varlığı sekans analizi ile doğrulandı.  MECP2'nin dördüncü eksonunda bilinen birkaç
delesyon tipi mutasyon bulunmaktadır.  PCR analizi ile iki hastanın ekson 4'ünde
yaklaşık 44 baz çifti delesyon bulundu.  Hastaların birinde yeni bir mutasyon –T197M-
saptanmıştır.  Normal karyotipe sahip bir erkek RTT hastasında R270X mutasyonu
saptadık.  Bu mutasyon normal MECP2 dizisi ile birlikte görüldüğü için hastada somatik
mozaisizm olduğu sonucuna varılmıştır.  Dört grup RTT hastası için MECP2 mutasyon
sıklığı sırasıyla: klasik-RTT için %37.2, RTT-varyant için %28.57, ve erkek-RTT grubu
için %25 olarak bulunmuştur.  Mutasyon tipi ile klinik semptomlar veya X kromozom
inaktivasyon profilleri arasında anlamlı bir ilişki bulamadık.
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1I. Introduction
1.1. Rett Syndrome
Rett Syndrome (RTT) is an X-linked dominant neurodevelopmental disorder
and the second most common cause, after Down syndrome, of severe mental
retardation in females (Christodoulou et al., 2001).  It affects children of all ethnic
groups and has an estimated incidence of 1 in 10,000 to 15,000 females (Kerr et al.,
1985, Hagberg et al., 1993, Leonard et al., 1997).
1.1.1 Identification of a new syndrome - RTT
Andreas Rett initially described RTT in 1966 but it was largely ignored until
1983, when Hagberg et al. published, the first description of a series of 35 patients,
in English (Rett et al., 1966, Hagberg et al., 1983).
RTT is characterized by the cognitive regression (relating to conscious
intellectual activity such as thinking, reasoning), deceleration of head growth, loss of
purposeful hand use with the development of stereotypic hand movements, tremors
(shaking from physical weakness), gait apraxia (loss of purposeful use of limb), and
seizures (a sudden attack, as of disease) occurring after a period of normal
development (Schanen et al., 1999) .
There are necessary and supportive criteria to diagnose RTT (Table 1).
Normal prenatal and perinatal period with normal developmental progress for the
first 6-18 months of life is essential for the diagnosis.  After normal head
circumference at birth, there is deceleration that leads to microcephaly.  Between 6
months to 3 years there is reduction or loss of acquired skills particularly purposeful
hand use, vocalisation (producing sound with the voice) and communication skills.
2The distinctive characteristic of RTT is the stereotypical hand movements such as
hand wringing, hand washing, clapping, patting or other more bizarre hand
automatisms.  Gait ataxia (an inability to coordinate voluntary muscular movements
that is necessary to walk on foot) is also an important feature. Supportive diagnostic
criteria include breathing dysfunction, electroencephalographic abnormalities,
spasticity, peripheral vasomotor disturbance, scoliosis (curvature of the spine), and
growth retardation.  If there is evidence of prenatal onset growth retardation,
microcephaly at birth, an identifiable metabolic, degenerative or storage disorder, an
acquired neurological disorder, retinopathy or optic atrophy, the clinical diagnosis of
RTT is excluded.  The nature of the condition is that of an evolving clinical
phenotype, making the clinical diagnosis uncomplete until 2 to 5 years of age
(Christodoulou et al., 2001).  An RTT patient displaying one of the features of the
disorder is shown in figure 1.
Table 1 Rett Syndrome Diagnostic Criteria (Christodoulou et al., 2001)
Necessary criteria Supportive criteria Exclusion criteria
1. Apparently normal prenatal
and perinatal period
2. Developmental progress
within normal range for the
first 5- 6 months
3. Normal head circumference
at birth, with subsequent
deceleration
4. Reduction or loss of
acquired skills (onset 6
months to 3 years) in
particular purposeful hand
use, vocalisation or speech
(words)
5. Appearance of marked
delay in development
6. Acquisition of hand
stereotypes
7. Gait and or truncal
apraxia(loss of purposeful
use of hand) (by 4 years)
1. Breathing dysfunction
2. Periodic apnoea during
wakefulness
3. Intermittent
hyperventilation
4. Breath holding
5. Forced expulsion of air or
saliva
6. EEG abnormalities
7. Slow wave background
with intermittent rhythmical
activity (3-5 Hz)
8. Epileptiform discharges,
with or without clinical
seizures
9. Spasticity, later with
muscle wasting dystonia
10. Peripheral vasomotor
disturbance
11. Scoliosis
12. Growth retardation
13. Hypotrophic, small, cold
feet
1. Evidence of prenatal onset
of growth retardation or
microcephaly
2. Organomegaly or other
evidence of storage disorder
3. Retinopathy or optic
atrophy
4. Existence of identifiable
metabolic or other
neurodegenerative disorder
5. Acquired neurological
disorder resulting from
severe infection of head
trauma
3Figure 1.  A girl with classical RTT phenotype.
Constant hand wringing, which is a typical symptom of RTT, is observed in
this girl. (Patient 00-173's photo was taken with permission from the family)
1.1.1.1. Natural History
The natural history of a typical patient with classical RTT is characterized by
the progression of four stages (see figure 1) (Hagberg et al., 1986). The patients are
normal at birth and exhibit normal development between 6-18 months. During stage
I, early onset of stagnation, obtaining of new skills slows and patients frequently
show autistic traits. Head growth slows and hypotonia is seen. After several months,
stage 2, the rapid regression stage slowly develops. Previously acquired skills such
as purposeful use of the hands and receptive and expressive language are lost and
there is gait apraxia.
4Figure 2.  Age of onset of signs and symptoms in RTT (Christodoulou and
Ellaway et al., 2001)
Also several unusual behaviours begin.  In Stage 3, the pseudostationary
stage, child's ability about interacting with her environment increases as autistic
features diminish.  Patients develop an irregular respiratory pattern while awake.
Seizures are most frequent during this stage and hand movements intensify.  Somatic
growth is poor and many patients develop osteopenia.  Stage 4, the late motor
deterioration stage, usually presents by 10 years of age and is characterized by
reduced mobility.  However there is no decline in cognition, communication or hand
skills. Repetitive hand movements may decrease.  Scoliosis is a prominent feature.
Rigidity (stiffness) and dystonia (increased muscle tone with abnormal extremity)
are characteristic.  The majority of RTT patients survive into adulthood.
51.1.1.2. RTT Variants
Females who carry out all of the diagnostic criteria for RTT are classified as
having typical or classical RTT.  However, the clinical expression of RTT also
includes atypical forms that may be more severe or mild in phenotype.  Five possible
RTT variants were described:
1. Infantile seizure onset type: The characteristic features of this form are
predominance of seizures and onset of the disorder before 6 months
(Hanefeld et al., 1985).
2. Congenital form: This form appears early without a period of normal
development, and involves congenital hypotonia and infantile spasms
(Nomura et al., 1985, Rolando et al., 1985).
3. Forme Fruste: This is the milder form that experiences less severe
regression and milder mental retardation and does not have seizures
(Hagberg et al., 1989).
4. Late childhood regression: In this case, regression has developed later
and more gradually than classic RTT (Gillberg et al., 1989).
5. Preserved speech variant (PSV): PSV shares with classic RTT some
symptoms like stereotypical hand-washing activities but differs in that
patients typically recover some degree of speech and hand use and
usually do not show growth failure (De Bona et al., 2000).
61.1.2. Hypothesis on the inheritance of the RTT gene
The genetic basis of Rett syndrome had been discussed extensively in the
literature following the identification of the syndrome.  Since 99.5% of all cases are
sporadic, it was not easy to define the inheritance pattern (Hagberg et al., 1983,
Martinho et al., 1990, Migeon et al., 1995, Comings et al., 1986, Ellison et al., 1992,
Zoghbi et al., 1988).  There were some clues about the possible genetic origin of the
syndrome such as almost exclusive occurrence in females, high concordance rate
among monozygotic twins while disconcordance among dizygotic twins, and
presence of rare familial cases (Comings et al., 1986, Ellison et al., 1992, Zoghbi et
al., 1988, Engerstrom et al., 1992, Schanen et al., 1997, Sirianni et al., 1998, Zoghbi
et al., 1990).  The first hypothesis by the help of rare familial cases, which indicated
inheritance through maternal lines and nonrandom patterns of X chromosome
inactivation (XCI) in obligate carrier females, suggested that Rett syndrome is an X-
linked dominant disorder caused by mutations in a gene that undergoes X
inactivation (Schanen et al., 1997, Sirianni et al., 1998, Zoghbi et al., 1990). There
were some argumentative hypotheses against this first one. This inheritance pattern
hypotheses included digenic inheritance of X-linked and autosomal loci (Buhler et
al., 1990) trinucleotide repeat expansions (Hofferbert et al., 1997), mitochondrial
inheritance (Ruch et al., 1989, Dotti et al., 1993, Lappalainen et al., 1994, Haas et
al., 1995a, Haas et al., 1995b, Tang et al., 1997), and autosomal dominant
inheritance with sex-limited expression (Killian et al., 1986).  Careful assessment of
the familial cases shown in figure 3, and analysis of the X inactivation patterns in the
putative carrier mothers, X-linked dominant inheritance became favourable again
(figure 3).  In addition, X inactivation studies performed in unaffected and obligate
carrier females displayed skewed X inactivation which favours the mutant X, and
7thus improves the phenotype (Willard et al., 1996, Puck et al., 1998).   II-2 in Rett
syndrome kindred 2, I-2 in Rett syndrome kindred 3, and I-2 in Rett syndrome
kindred 4 are the examples of the obligate carriers of Rett syndrome who were
mildly affected because of the skewed X chromosome inactivation (Migeon et al.,
1995, Schanen et al., 1997, Sirianni et al., 1998, Zoghbi et al., 1990).  Also in
discordant monozygotic twins, the preferential inactivation of paternal X
chromosome was reported (Migeon et al., 1995)
Figure 3. Pedigree for four RTT kindreds, which were used for mapping the
locus.
Filled symbols: Probands with classic RTT phenotype; Hatched symbols: Male RTT
patients (Schanen et al., 1999).
Rett Syndrome Kindred 1 Rett Syndrome Kindred 2
Rett Syndrome Kindred 3
I
II
III
1 2 3
1 2 3 4
1 2
21 3 4 5
1 2
1 2
1 2 3 4 5 6 7 8 9
Rett Syndrome Kindred 4
I
II
1 2 3 4
1 2 3 4
81.1.3. Localisation of the RTT locus via exclusion mapping
In order to map a locus, 3 strategies could be performed.  The first one is
linkage analysis.  This analysis was not proper for mapping RTT locus because
99.5% of all cases were sporadic so there were not enough families to perform
linkage analysis.  The second is cytogenetic analysis.  It was promising, and
conducted.  But, classical banding techniques, FISH and Southern blotting did not
detect any abnormalities such as translocations, microdeletions or duplications,
which would be consistent with an X-linked dominant disorder (Fan et al., 1999).
The third one, exclusion mapping, was the most suitable method for the localisation
of the RTT gene.
The basis of exclusion mapping is that because the related probands inherited
the same mutation, the defective gene must lie in a region of the X chromosome that
is shared by the probands (Schanen et al., 1999).  The first progress in mapping
came from the studies of RTT kindreds 1, 2 and 3 (figure 3).  These were maternally
related half-sisters and aunt-niece pair in these families (Ellison et al., 1992, Anvret
et al., 1990, Archidiacono et al., 1991).  Polymorphic X-linked markers were typed
for RTT kindred 1, 2 and 3, and the region near the marker was excluded if the
probands inherited different alleles.  Subsequently, a Brazilian family (RTT kindred
4) was identified, which further narrowed the critical region (Figure 3 and 4).  In
general, using the affected sister pairs for exclusion mapping was risky because the
mutation on the putative RTT gene could be transmitted through the paternal lineage
if the father was a germline mosaic.  But for RTT kindred 4, it was thought that the
inheritance was maternal since there were affected and unaffected sisters and skewed
X inactivation in the mother.  With the help of these four RTT kindreds, the RTT
9locus was mapped to Xq28, a particularly gene rich part of the genome, via
exclusion mapping (Schanen et al., 1997, Sirianni et al., 1998, Schanen et al., 1998).
Figure 4. The exclusion mapping
A. Pedigree of the Brazilian family and schematic diagram of extended haplotype
of each X chromosome.  The only region of X chromosome concordant for
RTT is indicated (Sirianni et al., 1998).
B. The regions excluded by the four RTT kindreds is summarized. Filled bars
indicate excluded regions. The loci flanking the discordant and concordant
regions are shown on the right. Ideogram shows the approximate cytogenetic
location (Schanen et al., 1999).
  
1.1.4. Candidate gene screening
In many disorders, after genetic mapping, transcripts within critical region were
identified and then were screened for mutations in probands.  The Human Genome
Project was instrumental in the increase of the number of genes that fall into the
minimal critical region which would be used for mutation screening in relatively few
families (Schanen et al., 1999, Dragich et al., 2000).  In order to choose the
candidate genes, the RTT pathology was used as a clue.  In RTT, obvious pathology
“Minimal Critical
Region” for RTT
A B
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was limited to the central nervous system (CNS) where there was evidence for
abnormal development or maintenance of affected neurons.  As a note, mosaicism
for the mutation was not apparent at the cellular level (Armstrong et al., 1998).
Initially, attention was largely directed toward genes expressed predominantly in the
CNS, and genes for neurotransmitter and their receptors, neural specific proteins
were excluded (Heidary et al., 1998, Percy et al., 1998, Van Den Veyver et al.,
1998, Narayanan et al., 1998, Cummings et al., 1998, Wan et al., 1998).  However
careful examination of female patients and more severely affected male patients
indicated that the RTT gene was also important for the function of other tissues
(Motil et al., 1994; Haas et al., 1997; Motil et al., 1998).  Finally, 14 years of search,
Amir et al. and Wan et al. broke the silence in RTT in late summer 1999, and
identified MECP2 mutations in RTT probands both in familial and sporadic cases.
1.2. Methyl-CpG binding protein 2 (MECP2) gene
1.2.1. Identification of  MECP2 gene
CpG dinucleotides are nonrandomly formed at much of the
heterochromatic regions of the chromosomes and the promoter regions of many
genes.  60-90% of CpG nucleotides in mammalian genome are modified by
methylation at the carbon 5 position.  The remaining non-methylated CpGs are
found in CpG islands that usually include functional promoters.  Methylation of
cytosine residues in CpGs is important both in stable silencing of heterochromatin
and reversible regulation of gene expression, however, it is not important for the
proliferation and in vitro differentiation of embryonic stem (ES) cells (Ng et al.,
1999a, Li et al., 1992, Tate et al., 1996).
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Two models were suggested for transcriptional repression based on
CpG methylation.  According to the first model, DNA is bound by proteins, which
preferentially interact with methylated CpG sites, and prevent binding of activators
or basal transcription factors.  Second model suggests that due to preferential
interaction between methylated DNA, ubiquitous components of chromatin may
alter chromatin structure and lead to transcriptional repression (Mostoslavsky et al.,
1997).
Initial efforts to identify protein-mediated CpG methylation-
dependent repression led to the identification of MECP1 (Meehan et al., 1989,
Boyes et al., 1991). After a year, a second member of MECP family was identified
and cloned in rat (Lewis et al., 1992), and in  the human (Adler et al., 1995).  This
member was named as MECP2.  Both of the members bind symmetrically
methylated CpGs with a sequence-independent manner (Boyes et al., 1991).
Although MECP1 required more than 10 CpG pairs to bind DNA (Boyes et al.,
1992), MECP2 can bind singly methylated CpG pairs (Lewis et al., 1992).  Although
there is functional homology between MECP1 and MECP2, different binding
specificity and expression patterns suggest that MECP1 does not compensate for the
loss of MECP2 function (Dragich et al., 2000).
  Mecp2 gene was found to be X-linked in the mouse (Quaderi et al.,
1994), and later studies placed MECP2 gene to human X chromosome in Xq28
between the interleukin I receptor-associated kinase (IRAK) and the color vision
(RCP/GCP) loci.  The MECP2 gene spans 76 kb and is composed of four exons that
is transcribed from telomere to centromere with 1461 nucleotide coding sequence
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(figure 5).  The 5' non-coding exon was identified recently by Reichwald et al.2000,
MECP2 is subjected to X-inactivation (D'esposito et al., 1996).
Figure 5. MECP2 is flanked by IRAK and RCP loci.
The direction of the arrows indicates the orientation of the transcription (Dragich et
al., 2000)
Although, expression of MECP2 was at low levels early in
development, it was expressed ubiquitously in embryonic and adult tissues
(Meehan et al., 1992). MECP2 has three transcripts, which vary in length.   Their
lengths are respectively 1.8kb, ~7.5kb and ~10 kb.  By the different use of
polyadenylation signals in 3'UTR, these three transcripts are formed.  Although
there is tissue-specific variation in expression, short (1.8 kb) and long (10 kb)
transcripts are present in most of the tissues.  The long transcript is found at higher
levels than the shorter one in brain and spinal cord.  They are expressed similarly in
kidney, thyroid, lung, gastrointestinal tract and adrenal glands.  The short one is
expressed at higher levels in skeletal and cardiac muscle, lymphoid tissues, liver
and placenta (D'esposito et al., 1996, Reichwald et al., 2000).  Although, there is a
low level of expression of the long transcript in the developing nervous system, the
expression is increased in postnatal hippocampus and olfactory bulb (Coy et al.,
1999).  Because of the identical half-lifes of the short and the long transcripts, the
difference between the functions of these transcripts is not fully understood yet
(Reichwald et al., 2000).
MECP2IRAK RCP
cen tel
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1.2.2. The structure and function of  MeCP2
MeCP2 is an abundantly expressed nuclear protein which is
associated with 5-methyl-rich heterochromatin (Tate et al., 1996, Nan et al., 1997).
Its 486 amino acids consist of four functional domains: (1) a methyl-CpG binding
domain (MBD; 85 amino acids in length) which is necessary to bind 5-methyl
cytosine in the major groove of DNA in the presence or absence of assembled
chromatin (Nan et al., 1993, Wakefield et al., 1999); (2) a transcriptional
repression domain (TRD; 104 amino acids in length) which interacts with
corepressor Sin3A to recruit histone deacetylases 1 and 2 (HDAC1and 2)(figure 6)
(Nan et al., 1998b, Jones et al., 1998); (3) a nuclear localization signal (NLS)
which may be responsible for the transport of MeCP2 into the nucleus (Nan et al.,
1996a, Nan et al., 1996b) and (4) a C-terminal segment which facilitates its binding
to the nucleosome core (Chandler et al., 1999).
 MeCP2 represses transcription through a mechanism that involves binding to
CpGs and recruitment of HDACs to modify chromatin structure.  This leads to
deacetylation of histones which allows DNA to wind more tightly around the
histone, and prevents the access of the transcription machinery to the promoters
(Jones et al., 1999, Wolffe et al., 2000).  However MeCP2 does not always require
deacetylase activity to repress transcription (Nan et al., 1998a, Kaludov et al., 2000,
Yu et al., 2000).  There is a interaction between MeCP2 and the transcriptional
machinery, which comprises TFIIB and E2F (Di Fiore et al., 1999).  This interaction
is an evidence for MeCP2 to repress transcription at a distance (>500 bp) (Nan et al.,
1997, Nan et al., 1998a, Kaludov et al., 2000).  Since, MeCP2 binds to the matrix
attachment sites, it may have a role in the architecture of silenced chromatin
(Buhrmester et al., 1995, Andrulis et al., 1998). These findings indicate that
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MeCP2’s role in nucleus is complex and mediate transcription through overlapping
mechanisms.
Figure 6. Schematic representation of the interaction between MeCP2 and
histone deacetylase complex.
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1.2.3. Mutations of MECP2
The mutation analyses have been focused on the coding region till
now because the untranslated regions of the gene is too long (particularly intron 1, 2
and 3'UTR).  MECP2 mutations have been reported in more than 300 RTT patients,
and up to %80 of the sporadic and %50 of the familial cases were found to have
mutations.  As a consequence of the sporadic occurrence of RTT, most mutations are
de novo. However, there are eight recurrent mutations namely R106W, R133C,
T158M, R168X, R255X, R270X, R294X, and R306C resulting from C to T
transitions that account for ~65% of mutations in patients (Amir et al., 1999, Wan et
al., 1999, Huppke et al., 2000, Cheadle et al., 2000, Bienvenu et al., 2000, Obata et
al., 2000, Hampson et al., 2000, Buyse et al., 2000, Inui et al., 2001, Vacca et al.,
2001, Bourdon et al., 2001, Nielsen et al., 2001, Erlandson et al., 2001).
The deletions found in the 3' end of exon 4 which account for 10% of
the known mutations are important for the function presumably because they are
involved in interaction of MECP2 with nucleosome core (Chandler et al., 1999).
More than 64 distinct mutations have been identified; most of them are nonsense
(approximately 41) although missense mutations (approximately 23) affecting highly
conserved amino acid residues are also seen.  Figure 7 shows the majority of the
mutations found in MECP2 gene and the mutations already associated with RTT is
summarized in appendix 3.
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Figure 7. Mutations identified in MECP2.
Exons 2-4 and the mutations of MECP2 is depicted in the diagram. Noncoding
regions is in black. MBD is in green and TRD is in red. Missense mutations are
listed above and nonsense mutations below the exons. The number of occurrence is
written in parenthesis near the recurrent mutations (Amir et al., 2000).
There is a high proportion of C to T transitions at CpG sites because
CpG dinucleotides are hypermutable, and germline and somatic mutations are
common at these sites (Rideout et al., 1990).  The mechanism that causes this
transition may involve methylation of 5' cytosine via methyltransferase and
spontaneous deamination of 5-methylcytosine to thymine.  C to T or G to A (on
antisense) transitions constitute ~55% single-nucleotide substitutions (Krawczak et
al., 1996).  There is a high level of CpG methylation in male germ cells.  Also the
whole X chromosome, including MECP2, is methylated (Girard et al., 2001).  The
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coding sequence of MECP2 contains 35 CpGs with a C to T transition possibility.
Exon 1 does not contain CpG pairs, which in part explains why no mutation has been
found in this exon.
1.2.4. Polymorphisms of MECP2
By using familial cases, ten different polymorphisms have been
identified (Amir et al., 1999, Wan et al., 1999, Cheadle et al., 2000, Buyse et al.,
2000, Amir et al., 2000a, Orrico et al., 2000).
Table 2   MECP2 polymorphisms identified.
Variant and Exon Nucleotide Change Amino Acid Change Domain
3 375 C to A I125 MBD
4 582 C to T S194
4 608 C to T T203M
4 843 C to T A281 TRD
4 897 C to T T299 TRD
4 984 C to T L328
4 1189 G to A E397K
4 1197 C to T P399
4 1233 C to T S411
4 1330 G to A A444T
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1.2.5. The effect of the mutations on the function of MECP2
Normal function of MeCP2 includes binding to 5mCs in the promoters,
recruiting deacetylase complex, and repressing transcription.  When there is a
mutation, MeCP2 no longer can bind to 5mC and can not recruit deacetylase
complex.  So, transcriptional noise from downstream genes appears to be likely (Van
Den Veyver et al., 2000) (figure 8).
Figure 8. Schematic representation of normal function of MeCP2 and the
effects of mutations to MeCP2 function (Van Den Veyver et al., 2000).
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MECP2 is expressed during organogenesis throughout the embryo, and,
later most strongly in the hippocampus (Coy et al., 1999).  Therefore, mutations of
this gene could impair several organs.  However, the MECP2 related genes that have
transcriptional repression activity and are members of repressor complexes could
compensate for MeCP2 dysfunction in some tissues other than the brain.  These
genes, MBD1, MBD2, MBD3, and MBD4 have been mapped to autosomes; and have
similar MBDs, but not TRD domains (Hendrich et al., 1999; Bird et al., 1999; Ng et
al., 1999; Wade et al., 1999) (figure 9).
Figure 9. MBD protein family
The MBD protein family shares conserved methyl-CpG binding domains. CxxCxxC
domain is found in MBD1. (GR)n represents, glycine-arginine repeats, and (E)
represents glutamic acid repeats. The "repair" domain of MBD 4 is a TG mismatch
glycosylase. TRD (transcriptional repression domain) is found only in MeCP2 (Bird
et al., 1999).
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In general, missense mutations are localized within the MBD domain,
except for R306C, which is found within the TRD, and impair selectivity for
methylated DNA.  Nonsense mutations, which truncate all or some part of the TRD
domain, affect the ability to repress transcription, and lead to a decreased level of
stability (Yusufzai et al., 2000; Ballestar et al., 2000).  Deletions are found within
the C-terminus, and affect the stability of the protein.
Majority of the nonsense mutation in the 5' end of the coding sequence
of MECP2 are proposed to result in the degradation of the mRNA molecule by a
mechanism called nonsense mediated decay (NMD).  This process monitors the
mRNAs for errors during gene expression and degrades them (Leeds et al., 1992
a,b).  In contrast, similar mutations within the last exon may by-pass this pathway
and result in the production of a truncated protein (Zhang J., 1998).  Since majority
of the mutations are nonsense and lie within the last exon, they are expected to
escape the NMD pathway.  In conjunction with this observation, a decrease in
disease severity was noted in cases that had truncating mutations within or
downstream of TRD when compared with the mutations within the N-terminal
region.  The nonsense mutations L138X, R168X, E235X, R255X, R270X, V288X,
and R294X were found to lead to the truncation of the TRD, and affect the ability to
repress transcription (Yusufzai et al., 2000).  A mutation resulting in the most
truncated protein was reported from an autistic RTT patient with a relatively mild
phenotype.  This Q19X mutation led to a gene product of only 19 amino acids.  This
example indicates that the premature truncation at the beginning of the protein does
not have to be the reason for a severe phenotype (Kim et al., 2000; Nielsen et al.,
2001).
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 The three recurrent RTT missense mutations, R106W, R133C, and
F155S have a greatly reduced (> 100-fold) affinity to the methylated DNA, which is
consistent with the impairment selectivity for binding to methylated DNA (Yusufzai
et al., 2000; Ballestar et al., 2000).  Another recurrent missense mutation, T158M,
which substitutes thr with met on the loop structure outside the DNA-binding
domain, shows only a small reduction (2-fold) in affinity to methylated DNA.
However, T158 in MECP2 is conserved from Xenopus to human and not present in
the other MBD family members, which suggest that this residue has a precise role
not related with its methyl-CpG binding activity (Dragich et al., 2000).
C-terminal region of MECP2 is required for protein stability (Yusufzai
et al., 2000).  Interestingly, this region shows an overall homology of 35% identity,
and 50% positivity in a 75 amino acid region with two brain-specific factors, brain-
specific factor-1 (BF-1) and fork head 4 (FKH4), which are members of the fork
head family. Their role is restricted to developing telencephalon.  This subregion
overlaps with -COOH terminus of MECP2, which has been shown to facilitate
MeCP2 binding to DNA (Chandler et al., 1999).
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1.3. MECP2 and X-linked mental retardation
Mental retardation is related with substantial limitations in mental
functioning.  In OMIM (Online Mendelian Inheritance in Man Database), 937
entries contained the term "MR", corresponding to 220 autosomal dominant, 437
autosomal recessive, 159 X-linked, and 121 non classified conditions.  IQ is used for
measuring MR; 50<IQ<70 means mild MR, and IQ<50 means severe MR.
Approximately 2-3% of the population has an IQ below 70. MR can be subdivided
into two: syndromic, which is characterized with consistent and distinctive clinical
finding (fragile-X is the most common one); and non specific (MRX) if MR is the
only primary symptom among affected individuals.  X-linked non specific MR
represents 5% of all MRs.  Eight genes have been identified which cause X-linked
MR when mutated.  These genes are OPHN1, GDI1, PAK3, ILRAPL, TM4SF2,
VCX-A and ARHGEF6 (figure 10).  However, their incidence is very low, being
around 0.5-1% of MRX (Toniolo et al., 2000; Castellvi-Bel et al., 2001).
Figure 10. The MR genes that are localized on the X chromosome (MECP2 not
included) (Castellvi et al., 2001).
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 Recently, mutations in MECP2 have been identified in four non
specific X-linked mental retardation families with multiple affected individuals.  In
the first family A140V mutation was identified in all of the four severely affected
males and two mildly affected females (Orrico et al., 2000).  E406X mutation was
identified in a three generation family in which two affected males display severe
MR and progressive spasticity (Meloni et al., 2000).  E137G mutation was found in
another MR family, and finally R167W mutation was found in a three-generation
family with four non-specific mentally retarded males (Couvert et al., 2001).  So far,
these mutations have not been reported in any one of the typical RTT cases.
There is a high frequency of mutations in MECP2 (~2%) when
compared with the other non specific X-linked MR genes (%0.5-1%).  This finding
indicates that MECP2 gene mutations are important for the MR phenotype (Couvert
et al., 2001).
In addition to MR, MECP2 mutations have been identified in patients
with Angelman syndrome phenotype (Imessaoudene et al., 2001; Watson et al.,
2001).
1.4. Male cases
Although RTT exclusively affects females, rare male cases have also been
reported.  Until now, five reports described mutations in male cases (Wan et al.,
1999, Clayton-Smith et al., 2000, Meloni et al., 2000, Orrico et al. 2000, Villard et
al., 2000).  Four of them are rare familial cases.  First one described a male child
with congenital encephalopathy who survived to age >1 year old (Wan et al., 1999).
Second described four brothers with severe nonspecific MR and movement disorders
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(Orrico et al., 2000). Third described two men affected by severe mental retardation
and progressive spasticity (Meloni et al., 2000).  Fourth described two brother who
died because of severe neonatal encephalopathy (Villard et al., 2000), and the fifth
described a sporadic case in which a boy affected by a nonfatal neurodevelopmental
disorder who has somatic mosaicism for a MECP2 mutation (Clayton-Smith et al.,
2000).
However MECP2 mutations are considered to be lethal for males.  In
addition, sex-limited expression of RTT can be explained by the occurrence of the de
novo X-linked mutations exclusively in the male germ cells which results in affected
daughters.  With this hypothesis, the absence of affected males can be explained by
the fact that sons do not inherit their X-chromosome from their fathers.  The
frequency of male-germ-line transmission of the mutation was found as 71% (Girard
et al., 2001) and 96.3% (Trappe et al., 2001).  These findings suggest that male
patients are naturally protected from de novo MECP2 mutations.
1.5. Mouse models for RTT
The unresolved issue in the pathogenesis of RTT is whether the
disease is the result of a dysfunction of postnatal neurons when the symptoms
become apparent or a prenatal developmental abnormality with postnatal phenotypic
appearance of the disease (Chen et al., 2001).  The most appropriate approach to
address this issue appears to be mouse studies.
The first mouse study indicated that Mecp2 is essential for
development, and its disruption leads to embryonic lethality (Tate et al., 1996).
Recent studies oppose this finding and demonstrated that Mecp2-null mice are
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viable, and show some of the symptoms of RTT at approximately six weeks of age
(Chen et al., 2001, Guy et al., 2001).
In both of these studies conditional knock-out technology was used to
delete exon 3 or exons 3 and 4 of MECP2.  Both in Mecp2-null mice and mice in
which Mecp2 was deleted in brain showed some of the symptoms of RTT such as
tremor, heavy breathing, and cold extremities indicating autonomic abnormalities
that are also characteristic for human RTT patients.  The most consistent changes
with the human RTT in mutant mice were smaller brain size and general reduction of
neuronal cell size (Chen et al., 2001, Guy et al., 2001).
1.6. Epigenetic regulation of gene expression and RTT
Methylation of CpG dinucleotides is necessary for transcriptional
repression and underlies the processes of X-inactivation, genomic imprinting, tissue-
specific and developmental regulation of gene expression (Cross et al., 1995).
1.6.1. X-inactivation
Dosage of X-linked genes is kept equal between females and males by
random X inactivation in each cell early in embryogenesis in females (Lyon et al.,
1986).  The exception for that is the genes in pseudoautosomal region which
normally escapes from X-inactivation and have functional homologues on Y
chromosome (Schneider-Gadicke et al., 1989, Goodfellow et al., 1984, Fisher et al.,
1990).
Two X-inactivation mechanisms, which can lead to RTT, were
hypothesized. The first, a mechanism in which the abnormality in X-chromosome
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inactivation leading to functional disomy of an X-linked gene(s), was proposed to
explain exclusive occurrence of RTT in females (Riccardi et al., 1986).  The
existence of male patients argues strongly against this disomy model (Schanen and
Francke, 1998).
The second is a more likely model which suggests that X-inactivation
patterns influence the phenotypic expression of RTT (Schanen et al., 1999).
Random X-inactivation pattern was found in most of the RTT cases (Zoghbi et al.,
1990, Anvret et al., 1990, Nielsen et al., 2001, Amir et al., 2000a, Webb et al., 1993,
Camus et al., 1996).  Skewed X inactivation, which leads to differences in
phenotypic expression was also observed in several non penetrant or mildly affected
obligate carrier females, and in an unaffected twin.  These results indicate that non
random pattern of X inactivation protects against the consequences of MECP2
mutations (Migeon et al., 1995, Schanen et al., 1997, Sirianni et al., 1998, Zoghbi et
al., 1990, Wan et al., 1999, Amir et al., 2000a, Krepischi et al., 1998, Villard et al.,
2001).  Recently, a case of RTT with 46,X,r(X) in which complete skewed
inactivation of the ring was shown.  Interestingly, no mutations were found in the
MECP2 gene present in intact X.  This finding suggested that, there could be two
loci related with RTT, one with the MECP2 locus which mutations predominantly
cause sporadic RTT.  The second is an unidentified locus in which mutations cause
mildly affected or unaffected carriers or familial cases (Rosenberg et al., 2001).
To evaluate the X-inactivation pattern, a rapid PCR methylation assay
has been developed for androgen receptor gene locus, where methylation of AR
locus correlates with X-inactivation.  In AR assay, which is widely used, the paternal
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allele can be distinguished from the maternal copy through the polymorphism of the
trinucleotide repeats in the locus (Allen et al., 1992)
1.6.2. Genomic Imprinting
Genomic imprinting is an epigenetic form of gene regulation that
determines expression or repression of genes according to their parental origin (Reik
et al., 1998, Jirtle et al., 1999).  This mechanism results in monoallelic expression of
the imprinted genes.  More than 25 imprinted genes have been identified.  These
genes have a role in fetal and placental growth, cell proliferation, and adult
behaviour (Jirtle et al., 1999, Barlow et al., 1995).
Methylation at CpG sites controls the multi step imprinting process.
In this process, the chromosome is methylated during gametogenesis or in the zygote
depending on its parental origin.  There is continuity in methylated state during cell
division and differentiation and the transcriptional machinery recognises the
methylated CpGs that result in monoallelic expression (Pfeifer et al., 2000).  Since
methylation-related transcriptional silencing underlies genomic imprinting, a role for
MeCP2 in this process can be thought.  However no data has been found about the
over or underexpression of imprinted genes as a consequence of MECP2 mutations
(Wan et al., 1999).
1.6.3. Developmental regulation of gene expression
During development, cells and tissues differentiate due to regulated
gene expression.  This regulation of gene expression can be performed in two levels
(Minie et al., 1992).  First is at the level of individual interaction of trans-acting
factors with local promoters and enhancers.  The stage-specific transcription factors,
which have a role in the regulation of B cell differentiation during development is a
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good example of this process (Hagman et al., 1994).  The second is at the level of
chromatin structure.  The developmentally regulated changes in histones determines
the repression of specific genes (Wolffe et al., 1996).
Since MeCP2 is a global transcriptional repressor, the mutations of
MECP2 can disrupt gene regulation in development by affecting trans-acting factors.
1.6.4. Tissue-specific gene expression
Although, the DNA content of all eukaryotic cells is identical, there
are different cell types.  The thing that makes this difference is the pattern of the
genes, which are expressed in the cell.  Briefly, the genes that are expressed define
the function of the cell.  Common housekeeping genes, which are expressed in all
cell types, perform the essential cell function.  The expression of other genes is
restricted to specific cell type with the help of tissue-specific gene expression
process (Strachan et al., 1996).
MeCP proteins bind to methylated CpG at a promoter and prevent
expression of the gene.  This process constitutes the cornerstone of the tissue
specificity.  It can be thought as the mutations of MECP2 can disrupt the tissue
specific gene expression.  But this hypothesis is highly unlikely since with impaired
tissue- specific gene expression process, the fetus would most probably be not
viable. Also there are functional and structural homologues of MeCP2 protein,
which can take over the impaired function of MeCP2.
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1.7. Aim and Strategy
The Rett syndrome project in our laboratory has the main aim of
studying the possible disturbances in DNA-methylation dependent gene silencing
which may be a new disease mechanism in human.  My specific aims in this project
are (1) Conformation of RTT diagnosis by DNA analysis.  For this purpose recurrent
MECP2 mutations will be analysed by restriction enzyme analysis and confirmed via
automated sequencing.  (2) Correlation of the phenotype (the symptoms) with the
genotype (the mutations).  (3) Correlation of the X chromosome inactivation patterns
with the clinical severity.
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2. Materials and Methods
2.1. Materials
2.1.1. Patient Samples
Collaborating physicians at Hacettepe University Medical Faculty (Ankara,
Turkey) referred Rett Syndrome patients to Bilkent University, Faculty of Science,
Molecular Biology and Genetics Department (Ankara, Turkey).  Blood samples
were collected in tubes containing EDTA.  Informed consent was obtained from the
parents of the patients.
2.1.2. Oligonucleotides
The primers used in the polymerase chain reactions (PCR), and the cycle
sequencing reactions were synthesized on the Beckman Oligo 1000 M DNA
synthesizer (Beckman Instruments Inc., Fullerton, CA, USA) at Bilkent University,
Faculty of Science, Department of Molecular Biology and Genetics (Ankara,
Turkey).  The primer sequences used for the analysis of MECP2 gene and AR gene
are given in Table 3 and 4.
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Table 3  Sequence of the MECP2 primers
Exons Name Sequence (5'→3') Expected
Size (bp)
[MgCl2]
(mM)
RTT 3 F GA 526 CCTGGTCTCAGTGTTCATTG
RTT 3 R GA 527 CTGAGTGTATGATGGCCTGG
597 1.5
RTT 4.1 F GA 530 TTTGTCAGAGCGTTGTCACC
RTT 4.1 R GA 531 CTTCCCAGGACTTTTCTCCA
380 1.5
RTT 4.2 F GA 532 AACCACCTAAGAAGCCAAA
RTT 4.2 R GA 533 CTGCACAGATCGGATAGAAGAC
380 1.5
RTT 4.3 F GA 534 GGCAGGAAGCGAAAAGCTGAG
RTT 4.3 R GA 535 TGAGTGGTGGTGATGGTGGTGG
366 1
RTT 4.4 F GA 536 TGGTGAAGCCCCTGCTGGT
RTT 4.4 R GA 537 CTCCCTCCCCTCGGTGTTTG
414 1.5
RTT 4.5 F GA 538 GGAGAAGATGCCCAGAGGAG
RTT 4.5 R GA 539 CGGTAAGAAAAACATCCCCAA
386 1.5
Table 4  Sequence of the AR primer pair
Exons Name Sequence (5'→3') Expected
Size (bp)
[MgCl2]
(mM)
RS-6 GA542 GTCCAAGACCTACCGAGGAG
RS-7 GA543 CCAGGACCAGGTAGGCTGTG
280 1
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2.1.3. Chemicals and Reagents
The chemicals and reagents used in this project were purchased from the
following sources:
Reagent Supplier
Acrylamide Sigma, St.Louis, MO, USA
Acetic Acid Carlo Erba, Milano, Italy
Agarose Basica LE, EU
Ammonium persulfate Sigma, St.Louis, MO, USA
Bisacrylamide Sigma, St.Louis, MO, USA
Boric acid  Sigma, St.Louis, MO, USA
Bromophenol blue  Sigma, St.Louis, MO, USA
Chelex  BioRad,Hercules, CA, USA
Chloroform  Carlo Erba, Milano, Italy
Ethanol  Merck, Frankfurt, Germany
Ethidium bromide  Sigma, St.Louis, MO, USA
Ficoll Type 400  Sigma, St.Louis, MO, USA
Formamide  Sigma, St.Louis, MO, USA
Glycerol  Carlo Erba, Milano, Italy
Hydrogen peroxide 40%  Carlo Erba, Milano, Italy
Isoamyl alcohol  Carlo Erba, Milano, Italy
Metaphor Agarose  FMC BioProd, Rockland, USA
NuSieve 3:1 Agarose  Basica LE, EU
Silver Nitrate  Sigma, St.Louis, MO, USA
Phenol  Carlo Erba, Milano, Italy
Proteinase K  Appligene-Oncor, USA
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Reagent Supplier
QIAquick PCR purification kit  Qiagen, Chatsworth, CA, USA
Sodium acetate  Carlo Erba, Milano, Italy
Sodium chloride  Sigma, St.Louis, MO, USA
Sodium dodecyl sulfate(SDS)  Sigma, St.Louis, MO, USA
Sodium hydroxide  Sigma, St.Louis, MO, USA
TEMED  Carlo Erba, Milano, Italy
TrisHCl  Sigma, St.Louis, MO, USA
Trisodium citrate  Sigma, St.Louis, MO, USA
Xylene cyanol  Sigma, St.Louis, MO, USA
pUC Mix Marker, 8  MBI Fermentas Inc., Amh, NY, USA,
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2.1.4. Restriction Enzymes
The restriction enzymes used in this project with their recognition and
restriction sites and the composition of the recommended buffers are listed in table
5.  The enzymes were obtained from the designated suppliers and used according to
the manufacturers' instructions.
Table 5  Restriction Enzymes Used for Mutation Detection
Restriction
Enzyme
Recognition Site Buffer (1X) Supplier
NlaIII 5’-CATG↓-3’
3’-↑GTAC-5’
NE Buffer 4
50mM potassium acetate
20mM Tris acetate
10mM magnesium acetate
1mM DTT
Biolabs
Beverly, MA, USA
NlaIV 5’-GGN↓NCC-3’
3’-CCN↑NGG-5’
NE Buffer 4
50mM potassium acetate
20mM Tris acetate
10mM magnesium acetate
1mM DTT
Biolabs
Beverly, MA, USA
HphI 5’-GGTGA (N)8↓-3’
3’-CCACT (N)7↑-5’
Buffer B+
10mM Tris-HCl
10mMMgCl2
0.1mg/ml BSA
MBI Fermentas Inc.
Amherst,NY,USA
HhaI 5’-G↓CGC-3’
3’-CGC↑G-5’
Buffer Y+
33mM Tris acetate
10mM magnesium acetate
66mM potassium acetate
0.1 mg/ml BSA
MBI Fermentas Inc.
Amherst,NY,USA
Hinf I 5’-G↓ANTC-3’
3’-CTNA↑G-5’
Buffer Y+
33mM Tris acetate
10mM magnesium acetate
66mM potassium acetate
0.1 mg/ml BSA
MBI Fermentas Inc.
Amherst,NY,USA
Eco130I (StyI)   AA
5’-C↓CTTGG-3’
3’-GGAAC↑C-5’
                TT
Buffer Y+
33mM Tris acetate
10mM magnesium acetate
66mM potassium acetate
0.1 mg/ml BSA
MBI Fermentas Inc.
Amherst,NY,USA
HpaII 5’-C↓CGG-3’
3’-GGC↑C-5’
Buffer Y+
33mM Tris acetate
10mM magnesium acetate
66mM potassium acetate
0.1 mg/ml BSA
MBI Fermentas Inc.
Amherst,NY,USA
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2.1.5. Polymerase Chain Reaction materials
The kits, which were used in PCR reaction, were obtained from MBI
Fermentas Inc. (Amherst, NY, USA).  Kits contained Thermus aquaticus DNA
polymerase (5U/µl), 10X PCR buffer (100 mM Tris-HCl (pH 8.8 at 25 °C), 500 mM
KCl, 0.8% Nonidet P40), 25 mM MgCl2 solution, and 10 mM dNTP mix (one ml of
10 mM dNTP solution contains 10µmol each of dATP, dCTP, dGTP, dTTP).  PCR
reactions were performed in 0.2 ml ThermowellTM tubes (Corning Costar Corp.,
Cambridge, MA, England) using the Gene Amp PCR system 9600 (Perkin Elmer,
Foster City, CA, USA).
2.1.6. DNA sequence analysis materials
Cycle sequencing reaction was performed using the ABI PRISMTM Ready
reaction Dye Terminator Cycle Sequencing Kit (ABI, Perkin Elmer, Foster City,
CA, USA).  The sequencing kit contained terminator premix with A-dye terminator,
C-dye terminator, G-dye terminator, T-dye terminator; dITP, dATP, dCTP and
dTTP; Tris-HCl (pH 9.0); MgCl2; thermal stable pyrophosphatase; and AmpliTaq
DNA polymerase, FS (8 U/µl).  Each kit also contained a PGEM  R 3 Zf(+) control
template (0.2 µg/µl) and -21 M13 forward primer (0.8 pmol/µl).  Cycle sequencing
reactions were performed in the Gene Amp PCR system 9600.  Electrophoresis was
performed using the 377 Sequencer (ABI,Perkin Elmer, Foster City, CA, USA).
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2.1.7. Standard Solutions and Buffers
Acrylamide:Bisacrylamide stock solution (%40)
39.5 acrylamide
0.53g bisacrylamide
The volume was adjusted to 100 ml by adding ddH2O.
Agarose gel loading buffer (6X)
15 % ficoll
0.05 % bromphenol blue
0.05 % xylene cyanol
Developer Solution
1.5 % NaOH
0.1 % formaldehyde
Extraction buffer
10 mM Tris HCl, pH 8.0
10 mM EDTA, pH 8.0
Proteinase K 20 mg/ml
0.5 % SDS
Fixative Solution
10 % ethanol
0.5 % acetic acid
Silver nitrate solution
0.1% silver nitrate
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Sequencing loading buffer
5 parts deionized formamide
1 part EDTA/ blue dextran
25mM EDTA (pH 8.0)
50 mg/ml blue dextran
SSC (20X)
3 M NaCl
0.3 M trisodium citrate, pH 7.0
TE Buffer
10 mM Tris HCl pH 8.0
  1 mM EDTA
Tris-boric acid-EDTA (TBE) (10 X) (1L)
108 g Tris HCl
  55 g boric acid
20 ml 0.5 M EDTA
q.s. 1000 ml ddH2O
2.2. Methods
2.2.1. DNA isolation from whole blood specimens
Blood samples have been stored at 40C for one to five days.  Before starting
DNA isolation, blood was frozen in 700 µl aliquots in 1.5 ml eppendorf tubes at -
800C for at least one day.
Blood was thawed, 800 µl of 1X SSC was added, and the content was mixed
by vortexing.  Then, it was centrifuged in a microfuge (Heraeus instruments,
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Biofuge, Osterode, Germany) at 13,000 rpm for 1 minute.  The supernatant was
removed without disturbing the cell pellet and discarded into disinfectant.  Then 1.4
ml 1X SSC was added and the tube was vortexed briefly to resuspend the cell pellet.
Again, it was removed, avoiding the pellet.  Cell pellet could be washed several
times with 1 X SSC if necessary.
Next, 800 µl extraction buffer (10 mM TrisHCl ph 8.0, 10 mM EDTA pH
8.0, 0.5 % SDS) and 10 µl proteinase K (20 g/ml ddH2O) were added.  The tube was
vortexed briefly to resuspend the cell pellet.  The suspension was incubated at 560C
for at least 1 hour.  Incubation could be done overnight if necessary to dissolve the
cell pellet.
The DNA was then extracted with 400 µl phenol/chloroform/isoamyl alcohol
(25:24:1) and vortexed for 60 seconds.  This step must be carried out in the fume
hood. The tube was spun in a microfuge for 5 minutes at 13,000 rpm.  The upper
aqueous layer (∼ 700 µl) was removed and placed in a new tube.  If DNA
supernatant was sticky or if the interface was not clear after this step, the supernatant
is not removed.  An additional extraction step was performed with 350 µl
phenol/chloroform/isoamyl alcohol.  The recovered supernatant was separated into
two or more tubes (350 µl per tube).
The DNA was then precipitated from the suspension by adding 35 µl NaOAc
(3M, pH 5.2) and 700 µl ice-cold absolute ethanol (EtOH) were added to each tube,
mixing by inversion and placing at - 200C for 30 minutes.  The tubes were spun in a
microfuge for 15 minutes at 13,000 rpm.  The alcohol was removed and the pellet
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was washed with 1.0 ml room temperature 70 % EtOH.  The tubes were spun in a
microfuge for 5 minutes at 13,000 rpm.  All the alcohol was removed with a
micropipette and the tubes were left open on the bench (∼30 min) to allow the EtOH
to evaporate. The DNA was solubilized in 200 µl TE (pH 8.0) by incubating at 560C
for at least 1 hour.  Incubation was done overnight if necessary to solubilize the
pellet. The DNA was then stored at - 200C.
The concentration and purity of the double stranded DNA was determined on
the Beckman Spectrophotometer Du 640 (Beckman Instruments Inc., Fullerton, CA,
USA) using the Beckman Instruments Du Series 600 Spectrophotometer software
program.  Absorbance readings were taken at wavelengths of 260 nm and 280 nm.
The A260 allows calculation of the concentration of nucleic acid in the sample.  An
optical density value of one corresponds to approximately 50 µg/ml of double
stranded DNA.  The A260/A280 ratio provides an estimate of the purity of the nucleic
acid.  A pure preparation of DNA will have A260/A280 ratio between 1.8- 2.0.  If there
is contamination with protein or phenol, the A260/A280 ratio will be significantly less
than the values given above and accurate quantitation of the amount of nucleic acid
will not be possible.
DNA was also checked by horizontal agarose gel electrophoresis to verify
that it was high molecular weight.  A 1.0 % agarose minigel with 1 X TBE was
prepared. Ethidium bromide (1 µl/ml) was incorporated into the gel.  DNA samples
were loaded into the sample wells and the gel was run at 80 V.  After the run, the
DNA was visualized with UV transilluminator.
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2.2.2 DNA isolation from hair
Procedures utilizing Chelex 100 chelating resin have been used for extracting
DNA from hair samples for use with the polymerase chain reaction.  The procedures
are simple, rapid and do not involve organic solvents.
Minimum 5-6 individual pieces of rooted hair was pulled out.  Then, it was
washed with 1-2 ml ddH2O.  Rooted hair was put into an eppendorf tube that
included 200 µl 5% chelex.  The mixture was incubated overnight at 56oC.  Then
vortexed for 10 seconds.
Next boiled for 8 minutes and vortexed for 10 seconds.  The tube was spun at
13.000 rpm for 2-3 minutes.  Then for PCR reaction, 10-20 µl was taken from
supernatant.
2.2.3 Polymerase Chain Reaction (PCR)
Polymerase chain reaction (PCR) is a technique, which is used to amplify the
number of copies of a specific region of DNA, in order to produce enough DNA to
be adequately tested.  There are three distinct events in PCR, which are repeated for
30 to 40 cycles: template denaturation, primer annealing and DNA synthesis.
Template DNA is denatured by heating the reaction to 95-960C.  After denaturation,
the primers are allowed to hybridize to their complementary single-stranded target
sequences.  The temperature of this step depends on the homology of the primers for
the target sequence as well as the base composition of the oligonucleotides.  The last
step is the extension of the oligonucleotide primer by the thermostable polymerase.
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720C is the ideal working temperature for the polymerase.  Usually, the larger the
template, the longer the time required for a proper extension.
Generally, 50- 100 ng DNA was used as a template.  A 25 µl PCR reaction
contained 2.5 µl 10 X PCR buffer (final concentration 1 X PCR buffer), 1.5- 3.0
mM MgCl2, 200µM dNTP, 20 pmol forward primer, 20 pmol reverse primer and 1
U Taq polymerase.  The volume was adjusted to 25 µl by adding ddH2O. Setting up
a series of PCR reactions using a range of MgCl2 concentrations optimised MgCl2
concentration for each primer pair.  Table 6 lists the appropriate MgCl2
concentration and melting temperatures for each exon.
Amplification was performed in the GeneAmp PCR with the following
parameters: initial denaturation at 950C for 5 min; 30 cycles of 950C for 30 sec
(denaturation), 57-620C for 30 sec (annealing), 720C for 30 sec (extension); and a
final extension at 720C for 10 min.  After the PCR cycles were completed, the tubes
were held at 40C for at least 5 minutes or until removal.
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 Table 6 Optimum MgCl2 concentrations and Tm for PCR of MECP2 and AR
  exons
2.2.4 Agarose Gel Electrophoresis
Agarose gel electrophoresis is a commonly used method for DNA analysis.
The method is based on the mobility of DNA molecules in the pores of agarose.
Agarose is a chain of sugar molecules, which is extracted from seaweed.  DNA has a
negative charge in solution, so it will migrate to the positive pole in an electric field.
The rate of migration will depend on the amount of charge and on the shape or size
of the molecule.
Genomic DNA and PCR products were analysed by using agarose gel
electrophoresis.  Agarose gels included agarose, 1X TBE and ethidium bromide (20
mg/ml). Runs were performed with 1 X TBE at 90 V for 30 minutes.
Gene Exons Primers
Tm
(0C)
[MgCl2]
(mM)
Exon 3 GA 526/527 62 1.5
Exon 4.1 GA 530/531 60 1.5
Exon 4.2 GA 532/533 58 1.5
Exon 4.3 GA 534/535 62 1
Exon 4.4 GA 536/537 58 1.5
MECP2
Exon 4.5 GA 538/539 60 1.5
AR Exon 1 GA 542/543 57 1
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2.2.5 Electrophoresis Markers
The length of DNA fragments were estimated by comparing to known
molecular weight standards that had been run on the same gel.  PUC mix,8
was used as DNA marker. The sizes of the fragments were given in figure
11.
Figure 11. Fragment sizes in pUC mix,8 DNA marker and φX174 DNA/HinfI
marker,10.
2.2.6 Restriction Enzyme Digestion
Restriction enzyme digestion of PCR products with HphI, NlaIII, NlaIV,
HhaI, HinfI, HpaII and StyI were performed in 20 µl reaction volumes.  Reactions
were carried out using the reaction buffer and conditions recommended by the
manufacturer.  One unit of enzyme was used to digest the PCR products.  In order to
determine the amount of PCR product that would be used in digestion, the PCR
samples were run on agarose gel before the digestion.  The incubation temperature
was 370C for all of the enzymes.  After digestion, heat inactivation was performed at
650C.
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After incubation the cut and uncut PCR fragments were analysed by agarose
gel electrophoresis.  DNA size markers were used to calculate the sizes of the bands.
Electrophoresis was performed using 3 % Nusieve 3:1 agarose or 2 % Metaphor at 5
V/cm in 1X TBE for 2.5 hours.  After the electrophoresis, the gel was stained in
EtBr (1µg / ml) for 20 minutes and then destained by two 15 minutes washes with
distilled water.
2.2.7 Polyacrylamide Gel Electrophoresis (PAGE)
Polyacrylamide gel electrophoresis is a high-resolution technique.  This
technique is based on the mobility of DNA molecules from negative pole to positive
pole upon voltage application through the porous structure of the polyacrylamide
gel.
12% nondenaturing gel was used for analysing the restriction enzyme
digestion results.  In order to prepare the PAGE, acrylamide / bisacrylamide from
40% stock, 10XTBE was mixed and the volume is completed to 40 ml with ddH2O.
10% APS and Temed was added to the mixture and poured to the PAGE apparatus.
The sample was loaded to the gel and runs are performed at 60 V for 3 hours.
2.2.8 Silver Staining
Silver staining is a method suitable for detection of double-stranded and
single-stranded DNA, and is more sensitive than ethidium bromide.
The steps in silver staining was as follows.  The gel was rinsed twice in
ddH2O for 1 minute.  Then it was incubated in 300 ml fixative solution for 3 minutes
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and it was rinsed again in ddH2O for 1 minute.  After this step, the gel was incubated
in 300 ml of 0.1% AgNO3 solution for 10 minutes at room temperature and rinsed
twice rapidly in  ddH2O.  As a last step, 300 ml of ice-cold developer solution was
added to the gel and incubated in this solution until the bands develop.
2.2.9 DNA sequence Analysis
The DNA sequencing analysis was performed using the ABI 377 DNA
sequencer at Molecular Biology and Genetics Department, Bilkent University.
DNA sequence analysis of MECP2 exon 3 for sample 99-91 using GA 526 and GA
527 primers, exon 4.1 for samples 99-114, 00-132, 00-157 using GA 530 and GA
531 primers, exon 4.3 for samples 99-104, 00-179, 00-187, 00-196 using GA 534
and GA 535 primers were performed.  Forward and reverse primer pairs were used
for sense strand and antisense strand sequencing.  The PCR products were cleaned
up with QIAquick PCR purification kit to remove the excess dNTP, MgCl2 etc.  The
purified PCR products were quantitated via agarose gel electrophoresis by
comparing band intensities with a DNA size marker of known concentration.  The
products with 20-100 ng/µl concentrations were sequenced.  For sequencing
reactions, Big DyeTM Terminator Cycle Sequencing Ready Reaction Kit ( ABI
Prism, Catalogue # 4303152) was used.  Cycle sequencing reaction was set up as
follows; 3-6 µl template, 1 µl primer and 4 µl terminator ready reaction mix was put
into 0.2 ml tubes and the volume is adjusted to 20 µl by ddH2O.  The reactions were
performed in Perkin Elmer GeneAmp PCR 9600 system according to the following
protocol: 25 cycles at 960C for 10 sec, at 500C for 5 sec, and at 600C for 4 min.
Sequencing products were precipitated using isopropanol.  Then DNA pellet was
resuspended in a sequencing loading buffer, and loaded in the 4% sequencing gel.
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During electrophoresis, the data was collected using ABI data collection
software.  After the run, these data were automatically analyzed by an ABI software.
Then the files that were analyzed were imported into Factura program to identify the
unambigous sequences and subsequently imported to Sequence Navigator program
for alignment with the reference DNA sequence.
2.2.10 Allele-specific X-chromosome inactivation assay
For this assay, genomic DNA (1µg) from the patients (who has a mutation)
was digested overnight, with methylation sensitive HpaII enzyme, in 25 µl volume,
by use of manufacturer's recommended buffer.  PCR amplification using GA 542
and 543 primers that amplify 280 bp AR gene was performed.  The PCR conditions
were; 950C for 5 min, followed by 30 cycles at 950C for 30 sec, at 560C for 30 sec,
and at 720C 30 sec with a final extension at 720C for 10 min.  The products were
separated on 12% PAGE and then visualized via silver staining.
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3. Results
3.1. DNA Isolation
Genomic DNA was isolated from patient's peripheral blood by using a
phenol chloroform extraction method (Ausubel et. al, 1994).  All extracted DNAs
were evaluated quantitatively and qualitatively by UV spectrophotometer, and
agarose gel electrophoresis.  DNA samples have an optic density ratio of 1.7-1.8.
The DNA samples represent single, high molecular weight band on agarose gel
(figure 12).   The concentrations of these DNA samples are 200, 160, 181 and 140
µg/ml, respectively.
Figure 12. DNA isolation by using phenol/chloroform extraction method
Samples were electrophoresed through a 1% agarose gel at 8V/cm for 35 min.
 Lane 1: 01-305; lane 2: 01-320; lane 3: 01-332; lane 4: 01-333
1 2 3 4
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3.2. Polymerase Chain Reaction
All PCR products were analyzed by agarose gel electrophoresis.  MECP2
exon 4.1 primers, GA 530, and GA 531 amplified samples shown in figure 13. The
expected size of the PCR product is 380 bp.  This was confirmed by comparison of
the observed DNA band with the size marker.  PCR mixture did not contain
contaminating DNA because there was no DNA band in the negative control sample
(Appendix 1 shows the schematic representation of the PCR products and primers
that were used in the sequence).
Figure 13. Analysis of PCR products
Samples were electrophoresed through a 2% agarose gel at 8V/cm for 35 min.
Lane 1: pUC mix DNA marker, 8; lanes 2-10: exon 4.1 samples; lane 11: negative
control
3.3. Detection of recurrent MECP2 mutations
Eight different types of mutations, one polymorphism and one deletion were
screened.  Since, RTT is an X-linked dominant disorder the patients are
heterozygous for the mutations.  Table 7 lists these mutations and polymorphism
(appendix 2 includes a figure that depicts the alterations, that were screened, in the
sequence of MECP2).
  1         2          3        4        5         6         7         8        9         10      11
380 bp
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Table 7 MECP2 mutations and polymorphism that are screened
3.3.1. R106W
A C316T point mutation was identified in two affected half sisters (Amir
et.al. 1999).  This point mutation is a missense mutation that changes Arg to Trp at
codon 106 within MBD.  The mutation occurs within the recognition site of the
restriction enzyme NlaIII and results in a gain of the cleavage site.  Thus, digestion
of MECP2 exon 3 PCR products with NlaIII might be a simple and cost-effective
assay for identifying the other Rett syndrome patients who inherited the same
mutation.
NlaIII has five recognition sites in the wild type MECP2 exon 3 DNA
sequence.  GA 526 and GA 527 primer pairs were used in the PCR reaction.  The
PCR amplified fragment is 597 bp.  After NlaIII digestion the expected fragment
StyI(+),MnIII(-)1189 G→AE397K-----4
Polymorphism:
NlaIV(-)806 delGV288XTRD4
NlaIV(-)808 C→TR270XTRD4
HphI(+)502 C→TR168X-----4
Nonsense:
HhaI(-)916 C→TR306CTRD4
NlaIII(+)473 C→TT158MMBD4
HinfI(+),TfiI(+)464 C→TF155SMBD4
NlaIV(-)455 C→GP152RMBD4
NlaIII(+)316 C→TR106WMBD3
Missense:
Restriction
Change (+/-)
Amino Acid
Change
Nucleotide
Change
DomainAlteration Type
and Exon
50
sizes are 156 bp, 152 bp, 141 bp, 67 bp, 50 bp and 31 bp.  When there is a R106W
mutation, a new NlaIII cleavage site is created.  In a heterozygous individual the
expected fragment sizes are 156 bp, 152 bp, 141 bp, 121 bp, 67 bp, 50 bp, 35 bp and
31 bp (schematically depicted in figure 14).
Amplified MECP2 exon 3 PCR products were incubated with NlaIII in the
recommended buffer at 370 C for 3 hours.  After digestion, the DNA samples were
analysed by polyacrylamide gel electrophoresis.
The NlaIII digestion result for individual 99-91 is shown in figure 15.
Restriction digestion of the 99-91 sample and a control sample with NlaIII results in
a pattern with extra fragments 121 bp and 35 bp (this band is not shown in figure) in
lenght, indicating heterozygosity for the R106W mutation in the patient sample, and
no extra fragments in the control sample.
DNA samples from 63 RTT patients were analyzed for R106W mutation
using this method.  Three patients were found to be heterozygous for R106W
mutation (99-91, 00-163 and 00-174).
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Figure 14. Expected NlaIII fragment sizes for wild type, mutant and
heterozygous individuals.
A. Black lines indicate the recognition / a cleavage site of NlaIII and the dashed
horizontal line indicates the mutation-induced cleavage site of NlaIII.
B. A schematic representation of the normal and mutant DNA samples run on
PAGE is shown.
152 bp
3’
141 bp
156 bp
NORMAL
152 bp
 67 bp
 50 bp
 31 bp
MECP2,Exon 3, 597 bp
RTT 3F-3R (GA 526-527)
R106W (Arg  →   Trp)
306 C → T
NlaIII(+) digestion(CATG )
67bp 121bp 35bp 152bp 141bp 50bp 31bp
A
B
MUTANT
152 bp
141 bp
 67 bp
 50 bp
 31 bp
 35 bp
121 bp
HETEROZYGOUS
141 bp
 67 bp
 50 bp
 31 bp
 35 bp
121 bp
156 bp
5’
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Figure 15. Detection of R106W mutation by cleavage with NlaIII enzyme.
DNA fragments were electrophoresed in 12% PAGE at 60 V for 4 hours.
Lane 1: pUC mix DNA marker, 8; lane 2: NlaIII-digested mutant 99-91; lane 3:
NlaIII-digested control.
3.3.2. P152R
A C455G point mutation was identified in one of the sporadic patients
(Cheadle et.al. 2000).  This point mutation is a missense mutation that changes Pro
to Arg at codon 152 within MBD.  The mutation occurs within the recognition site
of the restriction enzyme NlaIV and results in a loss of the cleavage site.
NlaIV has four recognition sites in the wild type MECP2 exon 4.1 DNA
sequence.  GA 530 and GA 531 primer pairs were used in the PCR reaction.  The
PCR amplified fragment is 380 bp.  When there is a P152R mutation, a NlaIV
recognition site is abolished.  In a heterozygous individual the expected fragment
sizes are 213 bp, 175 bp, 95 bp, 49 bp, 38 bp and 23 bp (schematically depicted in
figure 16).
 1       2       3 
121 bp
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Amplified MECP2 exon 4.1 PCR products were incubated with NlaIV in the
recommended buffer at 37 0 C for 3 hours.  As an uncut control, amplified MECP2
exon 4.1 PCR products were also incubated in the same NlaIV buffer, except
without the addition of enzyme.  After digestion the DNA samples were analysed by
agarose gel electrophoresis.
The NlaIV digestion result for individual 00-157 is shown in figure 17.
Restriction digestion of the 00-157 sample with NlaIV results in a pattern with
fragments of 213 bp, 95 bp, 49 bp and 23 bp in length, indicating heterozygosity for
the F155S mutation and 175 bp, 95 bp, 49 bp, 38 bp and 23 bp fragments in the
control sample.
DNA samples from 63 RTT patients were analyzed for F155S mutation
using this method.  Two patients were heterozygous for F155S mutation (00-133,
00-157).
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Figure 16. Expected NlaIV fragment sizes for wild type, mutant and
heterozygous individuals.
A. Black lines indicate the recognition / a cleavage site of NlaIV and the narrow
vertical line indicates the mutation-induced abolishment of cleavage site of NlaIV.
B. A schematic representation of the normal and mutant DNA samples run on
agarose gel electrophoresis is shown.
3’
MECP2, Exon 4.1, 380 bp
RTT 4.1F- 4.1R (GA 530-531)
P152R (Pro  →  Arg)
455 C   →  G
NlaIV(-) digestion(GGN NCC)
23bp 49bp 95bp 38bp 175bp
×
A
B
NORMAL
175 bp
  95bp
 49 bp
  23 bp
 38 bp
MUTANT
213 bp
  95bp
  23 bp
 49 bp
175 bp
 38 bp
HETEROZYGOUS
213 bp
  95bp
  23 bp
 49 bp
5’
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Figure 17. Detection of P152R mutation by cleavage with NlaIV enzyme.
DNA fragments were electrophoresed in 2% Metaphor at 60 V for 3 hours.
Lane 1: pUC mix DNA marker, 8; lanes 2-3; 5-6 : NlaIV-digested control; lane 4:
NlaIV-digested mutant 00-157 individual; lane 7: Uncut control
3.3.3. F155S
C464T point mutation was identified in a sporadic case (Amir et.al., 1999).
This point mutation is a missense mutation that changes Phe to Ser at codon 155.
The mutation occurs within the recognition site of the restriction enzyme HinfI and
results in a gain of the restriction site.
HinfI does not have a recognition site in the wild type MECP2 exon 4.1
DNA sequence.  GA 530 and GA 531 primer pairs were used in the PCR reaction.
The PCR amplified fragment is 380 bp.  When there is a F155S mutation, a HinfI
recognition site is created.  In a heterozygous individual the expected fragment sizes
are 380 bp, 197 bp and 183 bp (schematically depicted in figure 18).
1    2     3      4    5     6    7
175 bp
213 bp
380 bp
95 bp
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Amplified MECP2 exon 4.1 PCR products were incubated with HinfI in the
recommended buffer at 37 0 C for 3 hours.  As HinfI enzyme control, MECP2 exon
4.4 PCR product were incubated in the recommended buffer at 37 0 C for 3 hours.
After digestion, the DNA samples were analysed by polyacrylamide gel
electrophoresis.
The HinfI digestion result is shown in figure 19.  Restriction digestion of the
RTT samples of exon 4.1 result in pattern with 380 bp fragment, indicating that the
samples are wild type for F155S mutation.  Digestion of the HinfI-digested control
of MECP2 exon 4.4 with the enzyme results in a pattern with fragments 185 bp, 174
bp and 61 bp in length, indicating that enzyme is working.
DNA samples from 63 RTT patients were analyzed for F155S mutation
using this method. No F155S mutation was found.
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Figure 18.  Expected HinfI fragment sizes for wild type, mutant and
heterozygous individuals.
A. The sphered line indicates the mutation-induced cleavage site of HinfI.
B.  A schematic representation of the normal and mutant DNA samples runs on
PAGE is shown.
MECP2, Exon 4.1, 380 bp
RTT 4.1F-4.1R (GA 530-531)
F155S ( Phe  → Ser )
464 C   → T
HinfI(+) digestion(G ANTC)
197bp 183bp
A
B
MUTANT
197 bp
183 bp
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380 bp
      HETEROZYGOUS
380 bp
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Figure 19.  Detection of F155S mutation by cleavage with HinfI enzyme.
DNA fragments were electrophoresed in 12% PAGE at 60 V for 3 hours.
Lane 1: φX174 DNA marker, 8; lane 2-3: Normal RTT samples ( 00-163,
00-174); lane 4: HinfI-digested exon 4.4 control (99-95)
3.3.4. T158M
A C473T point mutation was identified in one of the sporadic patients (Amir
et.al. 1999).  This point mutation is a missense mutation that changes Tyr to Met at
codon 158 within MBD.  The mutation occurs within the recognition site of the
restriction enzyme NlaIII and results in a gain of the restriction site.
NlaIII does not have a recognition site in the wild type MECP2 exon 4.1
DNA sequence.  GA 530 and GA 531 primer pairs were used in the PCR reaction.
The PCR amplified fragment is 380 bp.  When there is a T158M mutation, a NlaIII
recognition site is created.  In a heterozygous individual the expected fragment sizes
are 380 bp, 197 bp and 183 bp (schematically depicted in figure 20).
185 bp
174 bp
61 bp
   1         2           3          4
380 bp
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Amplified MECP2 exon 4.1 PCR products were incubated with NlaIII in the
recommended buffer at 37 0 C for 3 hours.  After digestion, the DNA samples were
analysed by polyacrylamide gel electrophoresis.
The NlaIII digestion result for individual 99-107 is shown in figure 21.
Restriction digestion of the 99-107 sample with NlaIII results in a pattern with
fragments of 380, 197bp and 183 bp in length, indicating heterozygosity for the
T158M mutation and a single fragment of 380 bp in the control sample.
DNA samples from 63 RTT patients were analyzed for T158M mutation
using this method.  Five patients were heterozygous for T158M mutation (99-107,
00-132, 00-155, 00-188, 00-201).
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Figure 20. Expected NlaIII fragment sizes for wild type, mutant and
heterozygous individuals.
A.   The shingle line indicates the mutation-induced cleavage site of NlaIII.
B. A schematic representation of the normal and mutant DNA samples run on
PAGE is shown.
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Figure 21.  Detection of T158M mutation by cleavage with NlaIII enzyme.
DNA fragments were electrophoresed in 12% PAGE at 60 V for 4 hours.
Lane 1: φX174 DNA marker, 8; lane 2: NlaIII-digested mutant 99-107; lane 3:
NlaIII-digested control.
3.3.5. R168X
 C502T point mutation was identified in six unrelated sporadic cases (Wan
et.al. 1999).  This point mutation is a nonsense mutation that changes Tyr to stop at
codon 168 between the MBD and TRD.  The mutation occurs within the recognition
site of the restriction enzyme HphI and results in a gain of the restriction site.
HphI does not have a recognition site in the wild type MECP2 exon 4.1
DNA sequence.  GA 530 and GA 531 primer pairs were used in the PCR reaction.
The PCR amplified fragment is 380 bp.  When there is a R168X mutation, a HphI
recognition site is created.  In a heterozygous individual the expected fragment sizes
are 358 bp, 235bp, 123 bp and 22 bp (schematically depicted in figure 22).
1        2          31   2        3
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Amplified MECP2 exon 4.1 PCR products were incubated with HphI in the
recommended buffer at 37 0 C for 3 hours.  As an uncut control, amplified MECP2
exon 4.1 PCR products were also incubated in the same HphI buffer, except without
the addition of enzyme.  As HphI enzyme control, hMLH1 exon 14 PCR product
were incubated in the recommended buffer at 37 0 C for 3 hours.   After digestion,
the DNA samples were analysed by agarose gel electrophoresis.
The HphI digestion result is shown in figure 23.  Restriction digestion of the
RTT samples results in pattern with fragments 358 bp and 22 bp (not shown in
figure), indicating that the samples are wild type for R168X mutation.Digestion of
the HphI-digested control of hMLH1 exon 14 with the enzyme results in a pattern
with fragments 254 bp, 183 bp and 71 bp in length, indicating that enzyme is
working.
DNA samples from 63 RTT patients were analyzed for R168X mutation
using this method.  No R168X mutation was found.
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Figure 22. Expected HphI fragment sizes for wild type, mutant and
heterozygous individuals.
A. Black lines indicate the recognition / a cleavage site of HphI and the dashed
vertical line indicates the mutation-induced cleavage site of HphI.
B. A schematic representation of the normal and mutant DNA samples run on
agarose gel electrophoresis is shown.
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Figure 23.  Detection of R168X mutation by cleavage with HphI enzyme.
DNA fragments were electrophoresed in 4% NuSieve at 60 V for 3 hours.
Lane 1: pUC mix DNA marker, 8; lane 2: Uncut control; lane 3-4: HphI-digested
hMLH1 exon 14 control ( 97-2,97-168); lane 5: RTT sample (00-150)
3.3.6. R306C
A C916T point mutation was identified in one of the sporadic patients.  This
mutation is the first missense mutation identified in TRD (Wan et.al. 1999).  This
point mutation changes Arg to Cys at codon 306.  The mutation occurs within the
recognition site of the restriction enzyme HhaI and results in a loss of the cleavage
site.
HhaI has three recognition sites in the wild type MECP2 exon 4.3 DNA
sequence.  GA 534 and GA 535 primer pairs were used in the PCR reaction.  The
PCR amplified fragment is 366 bp.  When there is a R306C mutation, a HhaI
recognition site is abolished.  In a heterozygous individual the expected fragment
sizes are 308 bp, 164bp, 144 bp, 47 bp and 11 bp (schematically depicted in figure
24).
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Amplified MECP2 exon 4.3 PCR products were incubated with HhaI in the
recommended buffer at 37 0 C for 3 hours.  As an uncut control, amplified MECP2
exon 4.3 PCR products were also incubated in the same HhaI buffer, except without
the addition of enzyme.  After digestion the DNA samples were analysed by agarose
gel electrophoresis.
The HhaI digestion result for individual 00-179 is shown in figure 25.
Restriction digestion of the 00-179 sample with HhaI results in a pattern with
fragments of 308 bp, 164 bp, 144 bp, 47 bp and 11 bp in length, indicating
heterozygosity for the R306C mutation and 164 bp, 144 bp, 47 bp and 11 bp
fragments in the control sample.
DNA samples from 63 RTT patients were analyzed for R306C mutation
using this method.  Five patients were heterozygous for R306C mutation (99-95,00-
43,00-44,00-160,00-179).
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Figure 24. Expected HhaI fragment sizes for wild type, mutant and
heterozygous individuals.
A. Black lines indicate the recognition / a cleavage site of HhaI and the horizantal
brick line indicates the mutation-induced abolishment of cleavage site of HhaI.
B. A schematic representation of the normal and mutant DNA samples run on
agarose gel electrophoresis is shown.
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Figure 25.  Detection of R306C mutation by cleavage with HhaI enzyme.
DNA fragments were electrophoresed in 2% Metaphor at 60 V for 3 hours.
Lane 1: pUC mix DNA marker, 8; lanes 2 and 5: HhaI-digested control; lane 3:
Uncut control; lane 4: HhaI-digested mutant 00-179 individual.
3.3.7. R270X/V288X
 C808T point mutation was identified in three sporadic cases (Cheadle et.al.,
2000) and del806G was identified in all affected members of a two-generation
family (Wan et al., 1999).  C808T point mutation is a nonsense mutation that
changes Arg to stop at codon 270 within TRD.  Del806G causes a frameshift
mutation, after 19 missense amino acids, leads to a stop codon at position 288 within
the TRD.  These two mutations occur within the recognition site of the restriction
enzyme NlaIV and results in a loss of the restriction site.
NlaIV have a recognition site in the wild type MECP2 exon 4.3 DNA
sequence.  GA 534 and GA 535 primer pairs were used in the PCR reaction.  The
PCR amplified fragment is 366 bp.  When there is an R270X or V288X mutation,
this NlaIV recognition site is abolished.  In a heterozygous individual with R270X
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mutation, the expected fragment sizes are 366 bp, 314 bp and 52 bp and for V288X
mutation in heterozygous individual, the expected fragment sizes are 365 bp, 314 bp
and 52 bp  (schematically depicted in figure 26).
Amplified MECP2 exon 4.3 PCR products were incubated with NlaIV in the
recommended buffer at 37 0 C for 3 hours.  As an uncut control, amplified MECP2
exon 4.3 PCR products were also incubated in the same NlaIV buffer, except
without the addition of enzyme.  After digestion, the DNA samples were analysed
by agarose gel electrophoresis.
The NlaIV digestion result is shown in figure 27.  Restriction digestion of the
RTT samples results in pattern with fragments 366/365 bp, 314 bp and 52 bp (not
shown in figure), indicating that the samples are heterozygous for the R270X or
V288X mutation.
DNA samples from 63 RTT patients were analyzed for the R270X/V288X
mutations using this method.  Three patients were found to have a mutation. In order
to identify whether this mutation was R270X or V288X, DNA sequencing was
performed.  According to the result of the sequencing reactions, these three patients
had the R270X mutation (99-104, 00-187, 00-196).
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Figure 26. Expected NlaIV fragment sizes for wild type, mutant and
heterozygous individuals.
A. The diagonal brick line indicates the mutation-induced abolishment of cleavage
site of NlaIV.
B. A schematic representation of the normal and mutant DNA samples run on
agarose gel electrophoresis is shown.
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Figure 27.  Detection of R270X/V288X mutation by cleavage with NlaIV enzyme.
DNA fragments were electrophoresed in 2% Metaphor at 60 V for 3 hours.
Lane 1: pUC mix DNA marker, 8; lane 2: NlaIV-digested control; lane 3: NlaIV-
digested mutant 99-104 individual, lane 4: Uncut control
3.4 Detection of E397K MECP2 polymorphism by StyI
A C1189T polymorphism was identified in two unrelated families (Wan
et.al. 1999).  This polymorphism changes Glu to Lys at codon 397.  The alteration
occurs within the recognition site of the restriction enzyme StyI and results in a gain
of the cleavage site.
StyI has two recognition sites in the wild type MECP2 exon 4.4 DNA
sequence.  GA 536 and GA 537 primer pairs were used in the PCR reaction.  The
PCR amplified fragment is 414 bp.  When there is a E397K polymorphism, a StyI
recognition site is created. In a heterozygous individual the expected fragment sizes
are 237 bp, 135bp, 102 bp, 101 bp and 76 bp (schematically depicted in figure 28).
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Amplified MECP2 exon 4.4 PCR products were incubated with StyI in the
recommended buffer at 37 0 C for 3 hours.  After digestion the DNA samples were
analysed by polyacrylamide gel electrophoresis.
The StyI digestion result for individual 00-160 is shown in figure 29.
Restriction digestion of the 00-160 sample with StyI results in a pattern with
fragments of 237 bp, 135bp, 102 bp, 101 bp and 76 bp in length, indicating
heterozygosity for the E397K polymorphism and 237 bp, 101 bp and 76 bp
fragments in the control sample.
DNA samples from 60 RTT patients were analyzed for E397K
polymorphism using this method.  One patient who also bears R306C mutation was
heterozygous for E397K polymorphism (00-160).
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Figure 28. Expected StyI fragment sizes for wild type, mutant and heterozygous
individuals.
A. The grey line indicates the mutation-induced cleavage site of StyI.
B. A schematic representation of the normal and mutant DNA samples run on
PAGE is shown.
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Figure 29. Detection of E397K polymorphism by cleavage with StyI enzyme.
DNA fragments were electrophoresed in 12% PAGE at 60 V for 4 hours.
Lane 1: pUC mix DNA marker, 8; lane 2-4: StyI-digested control; lane 5: StyI-
digested 00-160 individual.
Totally, 18 mutations and 1 polymorphism were found in 69 RTT patients.
Table 8, indicates the samples which were found to have MECP2 mutations and
polymorphism.
Table  8  RTT patients with MECP2 alterations
  1            2           3            4           5
237 bp
135 bp
102/101 bp
 76 bp
Alteration Type 
and Exon Domain
Nucleotide Change Amino Acid 
Change
Restriction Change(+/-)
Frequency Samples
Missense:
2 MBD 316C      T R106W         NlaIII (+)  3 / 63 99-91,00-163,00-174
3 MBD 455C      G P152R         NlaIV (-)  2 / 63 00-133,00-157
3 MBD 464C      T F155S HinfI (+),TfiI (+)  0 / 63  ---------
3 MBD 473C      T T158M         NlaIII (+)  5 / 63 99-107,00-132,00-155,00-188,00-201
3 TRD 916C      T R306C         HhaI (-)  5 / 63 99-95,00-43,00-44,00-160,00-179
Nonsense:
3 ..... 502C      T R168X         HphI (+) 0 / 63  ---------
3 TRD 808C      T R270X         NlaIV (-)  3 / 63 99-104,00-187,00-196
3 TRD 806del     G V288X         NlaIV (-) 0 / 63  ---------
Polymorphism:
3 ..... 1189C      T E397K StyI (+),MnlII (-)  1 / 60 00-160
MECP2 ALTERATIONS
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3.5.  Detection of 3' deletion by PCR-based approach
For RTT patients, 00-45 and 00-184, after the PCR amplification of MECP2
exon 4.4 by the primers GA 536 and GA 537 there was a visible doublet on
acrylamide gel (figure 30).  Between the two bands in the gel, 44 bp difference is
calculated.  In that region, Buyse et al. 2000, reported a 44 bp deletion, 1164del44nt
and recently Nielsen et al. 2001, reported another 44 bp deletion, 1155 del 44nt, so
that, 00-45 and 00-184 was proposed to have 1164del44nt, 1155 del44nt or another
deletion with 44 bp.  Consequently, it needs to be analyzed subsequently by
subcloning and sequencing to indicate the type of deletion.
Figure 30.  Detection of 3' deletion at PCR level
Lane 1: pUC mix, DNA marker, 8; lane 2: 00-45; lane 3: 00-184, lane 4: 00-174,
lane 5: negative control
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3.6. Detection of unknown mutation
During the detection of T158M mutation via NlaIII enzyme digestion, 99-
114 sample displayed different pattern (figure 31).  There was ~ 310 bp extra band,
probably because of the creation of new recognition site for NlaIII.  Subsequent
analysis by sequencing indicated that there was C590T transition, which leaded to
T197M mutation in 99-114 individual (figure 36).
Figure 31. Detection of unknown mutation by cleavage with NlaIII enzyme.
DNA fragments were electrophoresed in 12% PAGE at 60 V for 4 hours.
Lane 1: pUC mix DNA marker, 8; lane 2: NlaIII-digested 99-114; lane 3: NlaIII-
digested control, lane 4: NlaIII-digested 00-155 with T158M mutation.
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3.7. DNA Sequence Analysis
3.7.1. MECP2 exon 3 R106W mutation
Cycle sequencing reactions were performed using MECP2 exon 3 primers,
GA 526 and GA 527 and ABI prism kit, for 99-91 sample in order to confirm that
the template had R106W mutation.  By using ABI Sequence Analysis Software on
the 377 DNA Sequencer, the DNA products were electrophoresed and analyzed.
Heterozygous bases were identified using the Factura software program.  Then,
finally the DNA sequence was aligned with the reference sequence using the
Sequence Navigator Software Program.  The only difference between the reference
sequence and 99-91 sample was at nucleotide 316 in exon 3.  At this position,
although there was C (cytosine) residue in the reference sequence, the 99-91 sample
was heterozygous "N" with one allele having a C (cytosine) residue and the other
allele having a T (tyrosine) residue at this point (figure 32).  Thus, after restriction
enzyme digestion results, it was confirmed by sequencing that 99-91, 00-163, 00-
174 samples had R106W mutation.
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Figure 32. Electropherogram showing R106W (306 C to T) mutation.
a. Sample 99-91: DNA sequence obtained with forward primer,
b. Sample 99-91: DNA sequence obtained with reverse primer.
3.7.2. MECP2 exon 4.1 P152R mutation
Cycle sequencing reactions were performed using MECP2 exon 4.1 primers,
GA 530 and GA 531 and ABI prism kit, in order to confirm the RE digestion result
for P152R mutation.  One of the sample found to be mutant by RE digestion, 00-
133, was sequenced.  By using ABI Sequence Analysis Software on the 377 DNA
Sequencer, the DNA products were electrophoresed and analyzed.  Heterozygous
bases were identified using the Factura software program.  Then, finally the DNA
sequence was aligned with the reference sequence using the Sequence Navigator
Software Program.  The only difference between the reference sequence and 00-133
sample was at nucleotide 455 in exon 4.1.  At this position, although there was C
(cytosine) residue in the reference sequence, the 00-133 sample was heterozygous
b
C/T
C/T
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"N" with one allele having a C (cytosine) residue and the other allele having a G
(guanine) residue at this point (figure 33).
Figure 33.  Electropherogram showing P152R (455 C to G) mutation.
a. Sample 00-133: DNA sequence obtained with forward primer,
b. Sample 00-133: DNA sequence obtained with reverse primer.
3.7.3. MECP2 exon 4.1 T158M mutation
Cycle sequencing reactions were performed using MECP2 exon 4.1 primers,
GA 530 and GA 531 and ABI prism kit, in order to confirm the RE digestion result
for T158M mutation.  One of the sample found to be mutant by RE digestion, 00-
132, was sequenced.  By using ABI Sequence Analysis Software on the 377 DNA
Sequencer, the DNA products were electrophoresed and analyzed.  Heterozygous
bases were identified using the Factura software program.  Then, finally the DNA
sequence was aligned with the reference sequence using the Sequence Navigator
b
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Software Program.  The only difference between the reference sequence and 00-132
sample was at nucleotide 473 in exon 4.1.  At this position, although there was C
(cytosine) residue in the reference sequence, the 00-132 sample was heterozygous
"N" with one allele having a C (cytosine) residue and the other allele having a T
(tyrosine) residue at this point (figure 34).
Figure 34.  Electropherogram showing T158M (473 C to T) mutation.
a. Sample 00-132: DNA sequence obtained with forward primer,
b. Sample 00-132: DNA sequence obtained with reverse primer.
3.7.4. MECP2 exon 4.3 R306C mutation
Cycle sequencing reactions were performed using MECP2 exon 4.3 primers,
GA 534 and GA 535 and ABI prism kit, in order to confirm the RE digestion result
for R306CM mutation.  One of the sample found to be mutant by RE digestion,
a
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00-179, was sequenced.  By using ABI Sequence Analysis Software on the 377
DNA Sequencer, the DNA products were electrophoresed and analyzed.
Heterozygous bases were identified using the Factura software program.  Then,
finally the DNA sequence was aligned with the reference sequence using the
Sequence Navigator Software Program.  The only difference between the reference
sequence and 00-179 sample was at nucleotide 916 in exon 4.3.  At this position,
although there was C (cytosine) residue in the reference sequence, the 00-179
sample was heterozygous "N" with one allele having a C (cytosine) residue and the
other allele having a T (tyrosine) residue at this point (figure 35).
Figure 35.  Electropherogram showing R306C (916 C to T) mutation.
a.     Sample 00-179: DNA sequence obtained with forward primer,
b.     Sample 00-179: DNA sequence obtained with reverse primer.
b
a
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3.7.5. MECP2 exon 4.3 R270X mutation
Cycle sequencing reactions were performed using MECP2 exon 4.3 primers,
GA 534 and GA 535 and ABI prism kit, in order distinguish the mutation type,
whether it was R270X or V288X. The samples which were found to had mutation
by RE digestion, 99-104, 00-187 and 00-196 were sequenced.  By using ABI
Sequence Analysis Software on the 377 DNA Sequencer, the DNA products were
electrophoresed and analyzed.  Heterozygous bases were identified using the Factura
software program.  Then, finally the DNA sequence was aligned with the reference
sequence using the Sequence Navigator Software Program.  The only difference
between the reference sequence and 99-104, 00-187 and 00-196 sample was at
nucleotide 916 in exon 4.3.  At this position, although there was C (cytosine) residue
in the reference sequence, the samples were heterozygous "N" with one allele having
a C (cytosine) residue and the other allele having a T (tyrosine) residue at this point
(figure 36). The sequence result of 00-196 will be explained and given in "somatic
mosaicism" section.
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Figure 36.  Electropherogram showing R270X (808 C to T) mutation.
a.   Sample 99-104: DNA sequence obtained with forward primer,
b. Sample 00-187: DNA sequence obtained with forward primer.
3.7.6. MECP2 exon 4.1 T197M mutation
Cycle sequencing reactions were performed using MECP2 exon 4.1 primers,
GA 530 and GA 531 and ABI prism kit, for 99-114 sample in order to identify the
different pattern, that leaded to mutation, after NlaIII digestion.  By using ABI
Sequence Analysis Software on the 377 DNA Sequencer, the DNA products were
electrophoresed and analyzed.  Heterozygous bases were identified using the Factura
software program.  Then, finally the DNA sequence was aligned with the reference
sequence using the Sequence Navigator Software Program.  The only difference
between the reference sequence and 99-114 sample was at nucleotide 590 in exon
4.1.  At this position, although there was C (cytosine) residue in the reference
sequence, the 99-114 sample was heterozygous "N" with one allele having a C
(cytosine) residue and the other allele having a T (tyrosine) residue at this point
(figure 37).  Thus, after restriction enzyme digestion results, it was identified a novel
mutation; T197M; in sample 99-114 by sequencing.
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Figure 37.  Electropherogram showing T197M (590 C to T) mutation.
a. Sample 00-132: DNA sequence obtained with forward primer,
b. Sample 00-132: DNA sequence obtained with reverse primer.
3.8. Somatic mosaicism for R270X mutation in a boy with classical RTT
A R270X mutation was identified in a boy, 00-196, with RTT.  Also this
mutation was detected in two girls with RTT (99-104, 00-187) (figure 38 B).  The
mutant allele in the affected boy was found along with the wild-type allele through
reduced dosage when compared with the samples of the females.  Although, the
mutant (T) and wild-type (C) nucleotide peaks were equal in the girls, the mutant
(T) nucleotide peak of 00-196 was lower than the wild-type nucleotide (C) peak.
(figure 38A a,b).   In order to perform dosage analysis of the alleles, genomic DNA
of 00-196 and 99-104 was re-amplified with the same primers used in sequencing
reaction, and digested again with NlaIV restriction enzyme.  The restriction
fragment's densitometric scanning revealed that the ratio is 56:44 in the girl and
36:64 in the boy (figure 38 B).
C/T
C/T
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Figure 38.  00-196 sample which is somatic mosaic for R270X.
A. Sequence analysis of samples 00-196 and 99-104,
B. Restriction digestion result of female 99-104 blood, male 00-196
hair root and 00-196 blood
Also restriction results from 00-196's PCR products from hair sample,
indicated similar ratio (figure 38 B). Cytogenetic analysis showed that 00-196 has
normal 46,XY karyotype. All these findings suggest that 00-196 is a somatic mosaic
for R270X.
A
b. 99-104 (female RTT)
a. 00-196 (male RTT)
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3.9. X-inactivation assay
The androgen receptor (AR) assay was used to assess X chromosome
inactivation pattern in RTT families (Allen et al. 1992).  This assay is based on the
differential methylation of a cytosine residue just 5' to the highly polymorphic
trinucleotide repeat in the androgen-receptor gene.  On inactive X this site is
methylated so that, is resistant to digestion by methylation-sensitive HpaII enzyme.
Conversely, the site is unmethylated on active X and susceptible to digestion. HpaII-
digested genomic DNA is used as a template for PCR reaction.  This amplification
product allows determination of the relative ratio of methylation of each allele,
corresponding to the ratio of inactivation.  The polymorphic triplet repeat, adjacent
to the methylation site, provides a length difference between the alleles. This
difference serves to separate the two alleles.  The X chromosome inactivation
pattern is considered skewed when the same X chromosome appears to be inactive
in ≥80 % of cells (Naumova et al. 1996).
The androgen-receptor assay was performed on genomic DNA from the
female RTT patients who has mutation of MECP2.  Figure 39 represents three of the
sample's, 00-133, 00-188, and 00-196 (male patient) AR assay results. Sample from
the male RTT patient with mutation is amplified only if undigested by HpaII, which
is consistent with the presence of a single active AR gene.  In all samples, except
sample 00-188 random X chromosome inactivation is found.  Table 9 summarizes
the result of X inactivation study.
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 Figure 39. X chromosome inactivation pattern of 00-133, 00-188, 00-196.
A. Lane 1: HpaII-digested PCR product of 00-133; lane 2: Undigested PCR
product of 00-133.
B. Lane 1: HpaII-digested PCR product of 00-188; lane 2: Undigested PCR
product of 00-188.
C.  Lane 1: Undigested PCR product of 00-196; lane 2: HpaII-digested PCR
product of 00-196.
Table 9  X inactivation patterns of RTT patients with MECP2 mutation
No
Family
Code Pt Code Domain Exon Base Change AA change
Mutation
designation
X-inactivation
(AR)
1 RTT-4 99-91 MBD 3 316 C to T Arg to Trp R106W random
2 RTT-34 00-163 MBD 3 316 C to T Arg to Trp R106W Not informative
3 RTT-42 00-174 MBD 3 316 C to T Arg to Trp R106W random
4 RTT-19 00-133 MBD 4 455 C to G Pro to Arg P152R random
5 RTT-28 00-157 MBD 4 455 C to G Pro to Arg P152R Not informative
6 RTT-18 00-132 MBD 4 473 C to T Thr to Met T158M random
7 RTT-51 00-188 MBD 4 473 C to T Thr to Met T158M Skewed
8 RTT-60 00-201 MBD 4 473 C to T Thr to Met T158M random
9 RTT-26 00-155 MBD 4 473 C to T Thr to Met T158M random
10 RTT-9 99-107 MBD 4 473 C to T Thr to Met T158M random
11 RTT-50 00-187 TRD 4 808 C to T - R270X random
12 RTT-8 99-104 TRD 4 808 C to T - R270X random
13 RTT-14 00-43 TRD 4 916 C to T Arg to Cys R306C random
14 RTT-15 00-44 TRD 4 916 C to T Arg to Cys R306C Not informative
15 RTT-6 99-95 TRD 4 916 C to T Arg to Cys R306C random
16 RTT-44 00-179 TRD 4 916 C to T Arg to Cys R306C random
17 RTT-31 00-160 TRD 4 916 C to T Arg to Cys R306C random
18 RTT-16 00-45 4 1163 del44nt - del random
19 RTT-48 00-184 4 1163 del44nt - del random
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3.10. Genotype-Phenotype correlations
 In order to compare the clinical features with the mutational spectrum in
MECP2, a detailed clinical scoring system was used.  The RTT patients harbouring
different mutations were assessed for fourteen clinical symptoms.  Three patients
were with forme fruste variant and sixteen with classical RTT.  Except one patient
the others can not use their hands. The other symptoms are highly variable (table 10
and 11).
The patients who harbour same mutation do not display similar symptoms.
As a result, there is not any consistent correlation between clinical severity and the
type of mutation.
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Table 10  Genotype-phenotype correlation
Pt Code Mutation
design.
Type of
RTT
Onset
(mo)
Ambulation Seizures Respiratory
dysfunction
Head
growth
Somatic growth
failure
Motor Hand
use
Communication Autonomic
dysfunction
EEG Scoliosis Self-
abuse
Screaming
99-91 R106W cl 3 0 0 1 3 1 0 3 1 0 NA 0 0 0
00-163 R106W FF 3 0 0 0 3 0 1 3 1 1 1 0 0 2
00-174 R106W FF 4 3 2 0 0 0 2 3 2 0 1 0 0 0
00-133 P152R cl 3 3 1 1 2 0 2 3 1 1 1 0 2 2
00-157 P152R cl 1 0 1 0 3 0 0 3 0 0 2 0 1 1
00-132 T158M cl 2 0 0 0 0 0 1 3 0 0 2 1 1 2
00-188 T158M FF 5 3 0 0 0 0 2 3 0 0 2 0 0 2
00-201 T158M cl 3 0 0 0 2 2 0 3 1 1 1 0 1 0
00-155 T158M cl 4 3 2 0 3 ? 2 3 1 1 1 0 2 1
99-107 T158M cl 2 1 2 2 3 2 0 3 ? 1 1 0 0 0
00-187 R270X cl 5 3 2 2 2 2 0 3 ? 1 ? 0 0 0
99-104 R270X cl 2 1 1 0 3 1 1 2 1 0 1 1 0 2
00-43 R306C cl 1 1 0 0 2 0 0 3 1 0 2 0 0 0
00-44 R306C cl 2 1 2 2 3 ? 1 3 1 1 ? 1 ? 1
99-95 R306C cl 1 2 2 3 3 2 0 3 1 1 ? 0 ? 1
00-179 R306C cl 1 0 1 0 3 0 0 3 ? 0 2 0 ? 0
00-160 R306C cl 1 1 1 1 3 0 1 3 1 0 2 0 ? 0
00-45 del cl 2 1 1 0 3 ? 0 3 1 ? 2 1 ? 1
00-184 del cl 2 0 0 0 3 1 1 3 ? ? 1 0 1 1
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Table 11  Severity score for RTT
Variable Sc. Definition Variable Sc. Definition
Age at onset 1 > 30 mo Hand use 0 feeds self
2 18-20 mo 1 holds objects
3 12-18 mo 2 may reach for objects
4 6-12 mo 3 none
5 < 6 mo
Ambulation 0 walks alone Communication 0 makes choices
1 walks with help 1 inconsistent eye gaze
2 used to walk 2 no communication
3 never walked
Seizures 0 None Autonomic dysfunction 0 none
1 well controlled 1 mild color/temperature changes
2 uncontrolled 2 moderate
3 infantile spasms 3 severe
Respiratory dysfunction 0 None Electroencephalogram 0 normal pattern
1 minimal cyanosis 1 multifocal and/or slow spike
2 intermittent cyanosis 2 slow spike; slow background
3 constant cyanosis 3 hypsarrhythmia
Head growth 0 none to minimal deceleration Scoliosis 0 none
1 deceleration > 10th percentile 1 minimal: <200
2 2nd-10th percentile after 24 mo 2 moderate: <200 -70
3 2nd percentile by 24 mo 3 severe >700
4 < 2nd percentile by 24 mo
Somatic growth 0 no growth failure Self abuse 0 none
1 mild failure 1 intermittent
2 moderate failure requiring 2 constant
oral supplements
Motor 0 none to mild ↑ or ↓ tone Screaming 0 none
1 moderate tone change and mild 1 < weekly
↓ ambulation 2 weekly or more
2 severe impairement of ambulation
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4. Discussion 
 
With the discovery of MECP2 mutations, Rett Syndrome became the 
first human disease found to be caused by defects in a protein involved in the 
regulation of gene expression through its interaction with methylated DNA (Amir et 
al., 1999, Wan et al., 1999, Ng et al., 1999a, Li et al., 1992, Tate et al., 1996). 
 
4.1. Mutation Analysis 
In this study 63 RTT patients classified as classical RTT (n=43), RTT 
variant (n=14), male RTT (n=4), and familial RTT (n=2) were screened for seven 
recurrent mutations (R106W, P152R, T158M, R306C, R168X, R270X, V288X), one 
rare mutation (F155S), and one polymorphism (E397K). Restriction enzyme analysis 
was used to analyze these known mutations.  DNA sequencing was performed to 
confirm the results (table 12).   
 
In the classical RTT group R106W was found in one (2.32%) patient, 
P152R in two (4.65%) patients, T158M in four (9.3%) patients, R306C in five 
(11.6%) patients, R270X in two (4.65%) patients, del 44 nt in two (4.65%) patients.  
E397K polymorphism was detected in one patient from this group.  
 
In the RTT variant group R106W was found in two (14.28%) patients, 
T158M in one (7.14%) patient, and the novel T197M mutation in one (%7.14%) 
patient. 
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Among the four male RTT patients one (25%) was found to carry the 
R270X mutation along the normal MECP2 sequence.  Finally, no mutation was 
detected among the familial cases.  R168X and V288X mutations were found in any 
one of the groups either.   
 
Table 12 Distribution of the mutations in the patient groups 
 RTT-classic 
(n=43) 
RTT-variant 
(n=14) 
RTT-male 
(n=4) 
RTT-familial 
(n=2) 
Mutation     
R106W 1 (2.32%) 2 (14.28%) 0 0 
P152R 2 (4.65%) 0 0 0 
F155S 0 0 0 0 
T158M 4 (9.3%) 1 (7.14%) 0 0 
R168X 0 0 0 0 
T197M 0 1 (7.14%) 0 0 
R270X 2 (4.65%) 0 1 (25%) 0 
V288X 0 0 0 0 
R306C 5 (11.6%) 0 0 0 
del 44 nt 2 (4.65%) 0 0 0 
Total 16 (37.2%) 4 (28.57%) 1 (25%) 0 
 
Although, R168X mutation has been reported as the most frequent 
mutation with frequency ranging from 12 to 39 % of all mutations found in the studies 
(Wan et al., 1999, Amir et al., 2000a), we did not see this mutation in our patients.  
Thus, R168X mutation is not considered as a common mutation in our Turkish RTT 
patients.  R168X mutation frequency might change from one population to another 
since it was found rarely also in the Swedish RTT patients (Erlandson et al., 2001).   
 
One novel mutation, T197M, was identified in one of our patients. It 
was known that because of the hypermutability of CpG sites, C to T transitions form 
the majority of the MECP2 mutations.  Consistent with this observation, the novel 
mutation that we identified is a C to T transition.  This C590T transition is found in a 
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region which is important for interaction of MECP2 with Sin3A which is a co-
repressor in the histone deacetylase complex (Nan et al., 1998b). Thus this mutation 
most probably affects the interaction of MeCP2 with co-repressor and disrupts the 
MeCP2- repressor complex integrity. 
 
While performing the mutation screening experiments, a boy who is 
mosaic for the recurrent R270X was identified.  After a boy who was reported as 
having somatic mosaicism in the MECP2 gene, our case is the second RTT patient 
who is mosaic for a MECP2 mutation (Clayton-Smith et al., 2000).  In the previous 
report the patient was mosaic for a rare MECP2 mutation.  However, in our case, he 
has somatic mosaicism for a recurrent MECP2 mutation. 
 
Somatic mosaicism has been reported in different genetic diseases 
including X-linked disorders; ornithine transcarbamylase deficiency (Maddalena et 
al., 1988), double cortex syndrome/X-linked lissencephaly (Gleeson et al., 2000), 
Duchenne muscular dystrophy (Bakker et al., 1989), and hemophilia A (Gitschier et 
al., 1989, Oldenburg et al., 2000).  Thus, somatic mosaicism should be considered 
when there is a male patient with an X-linked dominant disease. 
 
Our MECP2 mutation detection rate is 37.2% for the classical group, 
28.57% for the variant group, and 25% for the male group.  This rate can be increased 
by screening for other recurrent mutations such as R255X, and performing DNA 
sequencing for the entire MECP2 gene.  Since this was not cost-effective, it was not 
performed at this stage in our laboratory. 
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4.2. X-chromosome inactivation (XCI) 
To determine whether patterns of X chromosome inactivation 
contributes to phenotypic variability, 19 RTT patients with MECP2 mutations were 
evaluated.  16 patients who were analysed via AR assay were informative.  In these 
patients 15 has random and 1 has skewed X inactivation in blood.  Also, it was seen 
that the patient with skewed X-inactivation does not represent a milder phenotype.  
This may be due to somatic mosaicism for the X-inactivation patterns in different 
tissues. 
 
As a consequence, the X chromosome inactivation pattern can not be 
related to the phenotype which is consistent with the previous study (Nielsen et al., 
2001).  The random XCI pattern in most of the RTT patients suggests that the RTT 
phenotype is seen because of the high expression of mutant MECP2 in cells. 
 
 
4.3.  Genotype- Phenotype Correlation 
In reviewing the phenotypes reported for a mutation, a wide variability 
in each of the domains were examined (Amir et al., 1999, Wan et al., 1999, Amir et 
al., 2000a, Cheadle et al., 2000, Xiang et al., 2000, Bienvenu et al., 2000, Huppke et 
al., 2000).  Positive correlation between mutations and phenotype was reported only 
in Amir et al. 2000a.  A correlation was found between truncating mutations and two 
parameters: breathing abnormalities and low levels of CSF HVA (a breathing 
dysrhythmia, with periods of hyperventilation or apnea, breath-holding, interrupting 
normal breathing).  Also they showed that patients with missense mutations were 
more likely to have scoliosis than with truncating mutations (Amir et al., 2000a). 
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We did not detect any correlation between genotype and phenotype 
(table 10).  The correlation that was shown between truncating mutation and breathing 
dysfunction and missense mutation and scoliosis was not found in our RTT patients 
with mutations.  Except for one patient, the other patients can not use their hands.  
The other characteristics, including major clinical features are different from one 
patient to another. 
 
 
5. Future Perspectives 
  Since only seven recurrent mutations were screened until now, 
additional mutation analysis studies should be performed.  As a first step, R255X 
recurrent mutation can be screened via DNA sequence analysis, since this mutation 
does not make a change at the cleavage site of any enzyme.  Second, our RTT patients 
should be screened for mutations via DNA sequencing analysis for the entire coding 
region of the MECP2 gene.  Third, MECP2 introns can be analysed to see if structure 
or function of the gene is altered by intronic mutations.  
 
One of our male patients with classical RTT was found to be 
mosaic for the R270X mutation.  Single cell clones of this patient from blood cells 
can be obtained to analyse the global expression pattern of genes to better understand  
the underlying pathology in RTT.   
 
After completing the whole MECP2 gene mutation screening, a 
more comprehensive genotype-phenotype correlation can be performed and a 
consistent correlation between the symptoms and the mutations might be established. 
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As MeCP2 protein is involved in regulation of gene expression, it 
is likely that mutations of MECP2 will cause misregulation of downstream genes, 
which are normally silent.  This is probably the underlying pathology of clinical 
features in RTT.  There are a large numbers of genes on the X chromosome, which 
can be candidate downstream genes that are effected by MECP2 mutations.  These 
candidate genes can be analysed in cell lines derived from a single cell clone of RTT 
patients to understand whether there is inappropriate expression of the genes.  The 
result of this study might demonstrate if gene expression profile on the inactive X 
chromosome is altered in RTT or not. 
 
The other mechanism that is effected by methylation-dependent 
gene silencing is genomic imprinting.  In order to analyze the effects of MECP2 
mutations on the imprinting process genes subject to genomic imprinting can be 
analysed in RTT patients.  While methylation of imprinted allele is lost and imprinted 
allele is reactivated in cells with mutant MECP2, biallelic rather than monoallelic 
expression of imprinted genes would be recognized.  
 
The identification of mutations in MECP2 gene as the cause of 
RTT provides a good opportunity to study the pathogenesis of the disease at the 
molecular level.  As the mouse MECP2 gene is highly similar to the human gene, 
studies of the mouse gene may help us to establish an animal model for RTT.  Using 
the conditional knockout technology, mice that lack MECP2 either in all tissues or 
selectively in the brain was generated (Bird et al., 1999, Guy et al., 2001).  The 
mutant mice show features that are similar to those in RTT, including apparent normal 
pre- and perinatal development but fast postnatal deterioration.  These MECP2 mutant 
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mice can be analyzed, focusing on revealing any cellular defects associated with 
MeCP2 deficiency in the mouse central nervous system.  Since there is behavioral 
defects in RTT, it will be interesting to analyze whether there is also behaviral defects 
in mice.  The result of this study might help to cure the disease because of the 
identification of RTT pathogenesis. 
 
After identifying the function of MeCP2 totally, pathogenesis of RTT 
and the downstream gene products, a cure for RTT may be in reach.  Drugs, gene 
therapy and may be stem cell, with normal MECP2, transplantation can be the 
solution for the treatment of this syndrome. 
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Appendix 1. Schematic representation of the PCR product sizes and primers that were used to amplify the MECP2 gene. 
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Appendix 2. The mutations that were screened in MECP2 gene. 
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